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Dementia is a costly disease. Future projections show a higher share of elderly, which 
will increase prevalence of dementia and thus health care expenditures consumed by 
people with dementia. In addition, comes the costs of informal care. Caring for a 
loved one can make informal caregivers experience a high burden of care and high 
opportunity costs, even after the patient is moved to a nursing home. Dementia can 
also negatively affect the quality of life for the diseased person. Due to these factors, 
interventions that can decrease costs and positively impact the affected people are of 
high value to society.  
In 2015-2016, a randomized controlled trial, the COSMOS-intervention, was 
implemented in various nursing homes across Norway. The main objective was to 
improve quality of life in nursing home patients, with secondary objectives including 
improving cost-effectiveness and reducing unnecessary medication and hospital 
admissions. This thesis evaluates how the COSMOS-intervention affects quality of 
life, formal- and informal time use, and use of psychotropic medication in patients 
with dementia. To do so, the average treatment effect on the treated is estimated 
using regressions with individual fixed effects. Further, the thesis aims to investigate 
the economic implications of the intervention. The results show no change in quality 
of life, but a decreased use of psychotropic medication and informal care. Formal care 
has increased considerably. The causality of the results is challenged due to various 
factors, including a small sample size. Whether the changes can be considered 
economically beneficial, depends on whose perspective is taken, since costs and 
benefits are valued differently by the patient, nursing home management, and society. 
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There are almost 50 million people living with dementia worldwide (The Norwegian 
Health Association, 2017), and this number is expected to double within the next 
three decades (Husebo et al., 2015). With an estimated cost of $818 billion, global 
dementia care would be the 18th largest economy, if it were a country. This enormous 
sum exceeds the market value of large companies such as Apple and Google and 
following the future projections, is expected to grow massively in the coming years 
(Prince et al., 2015). Figure 1 shows that the costs worldwide are expected to rise to 
above $2000 billion1 in 2030. These numbers do not include informal care, which 
would increase the numbers considerably. 
 
Figure 1 Forecasted global costs of dementia (Source: World Alzheimer Report 2015) 
In Norway, it has been predicted that the number of people with dementia will 
increase from 78,000 today to around 112,000 in 2030, and to 200,000 in 20602. The 
cost of dementia is found to be 360,000 Norwegian kroner (NOK) per person per year, 
giving a staggering yearly cost of around 28 billion NOK (Vossius et al., 2015). The 
future projections indicate that these costs, and thus share of the health budged, will 
                                      
1 From my understanding, it must be a mistake in the figure from the original source. On the y-axis in 
Figure 1, it should say ‘billions’ and not ‘millions’. 
2 This number is uncertain because data from Norway doesn’t exist. For that reason, the prediction is 
based on data from other countries. The numbers for Norway will be available in 2020. 
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increase. It is therefore of major importance to utilize resources spent on people with 
dementia in an efficient way; and it will be even more so in the future. 
Much of the costs related to dementia is incurred through government expenditure on 
resource use. But the dementia disease has more than just a direct economic impact. 
Firstly, the person with dementia can experience reduced quality of life (QoL), higher 
mortality, ill health and disability. Secondly, family and friends are often the 
cornerstone for care and support, and thus time and attention that could have been 
spent working or on leisure activities, are devoted to caring for the diseased person. 
This is in the literature called informal care. Informal care is associated with 
opportunity costs of lost productivity (Prince et al., 2015) and health deterioration 
for the caregiver, and often constitutes a high care burden. A high care burden for 
both informal and formal caregivers, is often related to the fact that the majority of 
people with dementia develop stressful behavioral and psychological symptoms, also 
called neuropsychiatric symptoms, such as depression, agitation, hallucinations, and 
aggression.  
In the nursing homes (NHs) such care-related challenges raise the question of having 
labor-intensive or material-intensive manners of care. For instance, to control and 
monitor a resident’s behavioral problems, the decision of constant monitoring by staff 
versus use of chemical or physical restraints must be made (Cawley et al., 2006). A 
chemical restraint often used to prevent these behaviors are psychotropic drugs, like 
antipsychotics (Quinn, 2013). Psychotropic drugs, however, have been linked to 
negative health outcomes, such as increased risk of mortality and seizures. In a recent 
article, the Norwegian Broadcasting Corporation (NRK) shed light on today’s 
problematic use of psychotropic medication in elderly in Norwegian NHs (Sørbø and 
Moen Nilsen, 2018). Very large amounts of antipsychotics were given to an elderly 
patient as a mean to control the patient’s behavioral problem. Not long after, the 
patient was hospitalized, and she died a few weeks later. Though the reason for death 
is not clear, this shows that use of psychotropic medication in elderly is a relevant 
topic in Norwegian NHs today. Elderly NH patients often use many drugs, including 
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multiple psychotropic drugs, and the Norwegian Ministry of Health and Care Services 
states that one out of three NH patients use one or more superfluous drugs, and that 
approximately 10% of all hospital admissions are due to drug-related problems 
(Ministry of Health and Care Services, 2015). 
Since there is no current cure or treatment that can slow or stop the progression of 
dementia (Alzheimer's Association, 2017), trying to maximize the patients’ QoL can 
be the most important thing to do on a day-to-day basis. At the same time, we must 
take into consideration that resources are scarce and should be used efficiently. An 
intervention that can reduce costs and heighten QoL for people with dementia is 
valuable to society, when considering today’s situation and future projections of cost 
and prevalence. In my thesis, I will focus on NH patients with mild to severe 
dementia. More specifically, I will compare QoL, time use and use of psychotropic 
medication of patients with dementia in randomly assigned control and intervention 
groups which is a part of the cluster randomized clinical hybrid trial, COSMOS. The 
main purpose of the COSMOS-study is to measure the effect of a randomized 
controlled intervention on QoL. In addition to investigate the effect on QoL, I will 
exploit the randomization to further evaluate the effect of the intervention on 
resource use. Due to data availability, resource use is restricted to mean formal- and 
informal time use and use of psychotropic medication. 
The two main purposes of the thesis are: (1) Evaluate how the COSMOS-intervention 
affects the QoL in people with dementia, and their use of psychotropic medication, 
formal care, and informal care. (2) Investigate the economic implications of the 
intervention.  
The structure is as follows: Chapter 2 puts dementia, and especially the cost of 
dementia, in the context of Norway today. Chapter 3 examines the empirical 
literature. Chapter 4 describes the COSMOS-study and the sample data. Chapter 5 
details the methodology and estimation strategy. Chapter 6 presents the results, 
while Chapter 7 discusses the findings in light of the literature and specifically 




This chapter gives a picture of the economic motivation of studying the population of 
people with dementia. It specifically examines the cost of dementia in more detail, 
and also describes Norway’s expenditures on health and the elderly; a population in 
which people with dementia will be a larger share of in the coming years. Further, a 
current governmental plan concerning dementia is presented, showing that 
interventions focusing on dementia are of public interest in Norway today.  
2.1 Public health expenditures  
The demand for health care is increasing, and we can expect to spend more on health 
in the future. The contribution is especially large from the growing share of elderly, 
following the changing demographics that is evident all over the world. Today, 
875,000 people in Norway, or approximately 17 % of the population, are 65 years old 
or older, and Norway has never before had a proportion of elderly this large 
(Statistics Norway, 2017). This group is expected to increase to 21% of the 
population by 2050. Since the greatest risk factor of dementia is increasing age 
(Alzheimer's Association, 2018), the future projections of growing elderly leads to a 
higher incidence of dementia, and thus costs related to this disease. 




From 2011 to 2015, the total expenditures on health care increased by around 20,000 
million NOK. The spending on NHs (inpatient long-term care) has also increased, 
with around 2,500 million NOK. The age group of patients >67 years old, stands for 
most of the resources used on NHs and similar long-term residential facilities, where 
nine of ten NOK are used on the elderly in these facilities (Statistics Norway, 2013). 
As 80% of NH patients are found to have dementia (Selbæk et al., 2007), the 
majority of NH costs are related to people with dementia.  
2.2 Cost of dementia in Norway 
Vossius et al. (2015) have tried to map the total resource use and cost of dementia-
related illness in Norway in the nation-wide report Resource Use and Disease Course 
in Dementia (REDIC). The following cost estimations of direct, indirect and 
intangible costs are found in this report. 
It is calculated that one patient with dementia will use health and care services for 
approximately 2.9 million Norwegian kroner (NOK), where NH costs counts for 
almost two-thirds of the total costs. The total cost of people with dementia is 
calculated to 28 billion NOK per year. These numbers do not include informal care. 
During the course of the disease, staffing-resources equal to 3.37 man-years are used. 
In total, 32,451 man-years in health and care services are spent on people with 
dementia per year, while it in NH locations are spent 1.06 man-years per patient per 
year.  
There are approximately 28,091 people with dementia in Norwegian NHs. About half 
of the NH patients receive informal care from loved ones, with an average of 6.7 
hours per month. This is valued between 0 and 2466 NOK, depending on the 
assumed pricing, e.g. no wage or a nurse’s wage. 
When it comes to QoL, Vossius et al. (2015) find that it seems like people with 
dementia perceive their QoL equally good as their peers without dementia. At the 
same time, they find consistent reporting of health care personnel and next of kin 
valuing QoL lower than the patients themselves. Thus, they conclude that society 
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value the illness of dementia with lower health related QoL, and that the personal 
experience of higher QoL is probably not actual, but merely a symptom of the 
disease. If this valuation is used, each person with dementia will lose 1 quality-
adjusted life year (QALY) because of reduced health related QoL. When higher 
mortality is considered, dementia stands for a loss of 4.2 QALYs per patient. 
Vossius et al. (2015) also evaluate how much the costs of psychotropic medication 
amounts to in the dementia care. They find that people with dementia have 4.3 times 
higher costs of psychotropic medication than people without dementia. The monthly 
cost is 111 NOK per patient and amounts to less than 1% of the total costs per 
month. These estimates are based on price and quantity and does not take into 
consideration how QoL can be affected by use of these drugs. 
2.3 The Dementia Plan 2020 
The Government of Norway (hereafter the Government) recognizes dementia of 
current and future importance and has dementia care and research on its agenda. As 
the first country in the world, Norway presented an individual plan for the services 
that affects people with dementia. Dementia was put on the Government’s agenda 
with the Dementia Plan 2015, and has stated that “One of the biggest care challenges 
we face […] is the expectation of twice as many people in the next 35 years with 
various dementia disorders (Ministry of Health and Care Services, 2008, p.7). The 
Dementia Plan 2020 is built on experiences from the Dementia Plan 2015 and was 
published by the Norwegian Ministry of Health and Care Services in 2015 as a 
guidance to dementia care for the years 2016-2020. It strives to improve the services 
offered to people with dementia and their next of kin. The strategies and measures in 
the plan are  
“intended to help put dementia and its challenges on the agenda of ordinary 
municipal planning. The aim is to ensure long-term, integrated planning for the 
local community and the physical environment, and high-quality services 
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designed to meet the needs of the growing number of people with dementia and 
their families.” (Ministry of Health and Care Services, 2015, p.9).  
The plan includes many strategies and measures to reach these aims, such as 
providing support and help for informal caregivers by establishing an informal care 
program to respite the caregiver, and securing “better procedures to ensure correct 
medication management for older people in general and people with dementia in 
particular” (Ministry of Health and Care Services, 2015, p.32). A part of the long-
term strategy is combating the extensive use of psychotropic drugs such as 
antipsychotics and other psychiatric drugs.  
3. Empirical literature  
Together, dementia, QoL, psychotropic drugs, and formal- and informal care have 
wide economic implications, concerning different types of costs. There exists literature 
to various degrees regarding these topics and the association between them, though 
the causal relationships are explored to a smaller degree. This chapter presents a 
selection of empirical literature attempting to shed light on informal care, QoL and 
its relationship with resource use, and the relationship between psychotropic drugs 
and formal care in a NH setting for people with dementia. 
3.1 Quality of Life 
QoL is defined by WHO as “an individual's perception of their position in life in the 
context of the culture and value systems in which they live and in relation to their 
goals, expectations, standards and concerns” (World Health Organization, 2017). For 
a person with dementia, QoL is affected by the consequences of the disease, including 
present and future forecast, for example, on cognitive abilities. Factors that can 
further influence QoL in people with dementia is loss of independence, side-effect of 
drugs, incontinence, social isolation, paranoid reactions, sleeplessness, hallucinations 
and delusions, and depression (Korczyn and Davidson, 1999). 
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In studies connecting QoL and dementia, the findings vary. QoL in people with 
dementia has been associated negatively with impairment in activities of daily living 
(ADL), severity of dementia and cognitive impairment3, neuropsychiatric symptoms, 
depression and pain (Mjørud et al., 2014, Barca et al., 2011, Rostad et al., 2017, 
Sloane et al., 2005). Sloane et al. (2005) found that ADL-function was the strongest 
predictor of QoL scores. Depressive symptoms and agitation was also associated 
negatively with QoL, although these factors explained less of the variance. Pain, on 
the other hand, showed little association with QoL in this study. Due to the cross-
sectional designs of these studies and for the lack of randomization, one cannot make 
any causal conclusions, only imply associations. Cross-sectional studies do not follow 
the same individual over time but observe the sample at a specific point in time. We 
thus do not know if something underlying are affecting the results, how they would 
change for the same person over time, or if one factor is causing the other. 
In other words, QoL in dementia seems to be complex and the empirical findings are 
inconsistent, which can make it difficult to identify and quantify how and why 
dementia affects QoL. Additionally, due to the disease’s impact on the brain, 
especially in cases of severe dementia, many patients find it hard, or even impossible, 
to communicate how he or she feels. This leads to the need of a proxy assessment, 
performed by the people that are closest to the patient. 
An issue is that proxy-rating can be biased by the proxy-rater, as people are not 
neutral beings. In a recent systematic review, Robertson et al. (2017) found that 
proxy-rated QoL were rated lower where cognitive impairment was higher for care 
home residents with dementia. This may reflect how the observer’s view of the 
patient’s health status has changed, or how the observer would feel if in a similar 
situation (Moyle and Murfield, 2013). Specifically, proxy-rated QoL in long-term care 
residents with dementia are found to be different from patient-rated QoL (Sloane et 
al., 2005). In the Norwegian context, Vossius et al. (2015) found that next of kin 
                                      
3 Cognitive impairment is in the literature used as a synonym for dementia. Higher cognitive 
impairment is equivalent to more severe dementia. 
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considered NH patients’ QoL as lower than that experienced by the patients 
themselves. On the other hand, it has also been found reasonable compliance between 
proxy rating between staff and relatives (Robertson et al., 2017) and between proxy- 
and patient-rating (Essen, 2004), even though the latter found that moderate 
cognitive impairment was associated with lower compliance. So, QoL can be 
underestimated and the validity questioned. Still, proxy rating is important for 
individuals that cannot express themselves – secondhand information is better than 
none information at all. 
3.2 Resource use in nursing homes 
3.2.1 Formal care 
Dementia includes a wide range of symptoms related to decline in memory or other 
thinking abilities that have an impact on a person’s everyday activities (Alzheimer's 
Association, 2017). People with dementia often end up in a NH, either because they 
can no longer take care of themselves, or because family and relatives can no longer 
look after them. In Norway, after the diagnosis has been given, half of the people 
with dementia move to a NH within three years (Vossius et al., 2015). 80 % of 
patients in Norwegian NHs are found to have dementia (Selbæk et al., 2007, Bergh et 
al., 2012). They require excessive care, which increases along with the progression of 
the disease. They need help in ADL and other tasks, and NH staff provide extensive 
assistance with dressing, personal hygiene, transfers, toileting, communication, bed 
mobility, locomotion, and eating (Carpenter et al., 2006, Matsubasa et al., 2015). 
Formal care and Dementia 
Some research has tried to identify how dementia affects the staff’s time use. In a 
Swedish longitudinal population-based study on aging and dementia, Nordberg et al. 
(2007) found that the dependency of formal care in ADL was higher in people with 
dementia, than of people without dementia. Having dementia and dependency of care 
in ADL was significantly associated with use of care time. Including age, gender, 
comorbidity and informal care into the model did not change the results. In the 
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Norwegian context, Vossius et al. (2015) found that functional disability, cognitive 
impairment, neuropsychiatric symptoms, and generally bad health were associated 
with increased resource use on an individual level for people with dementia. 
Functional disability had the strongest association. In a NH context, they found that 
most residents needed help in tasks related to ADL and instrumental ADL (IADL), 
while only around half needed supervision. ADL-tasks had the highest use of care-
hours on average. Overall, it seems like dementia is associated with higher resource 
use, where especially impairment in ADL, or functional disability, contributes to an 
increased use of formal care.  
Formal care and QoL 
Elderly NH patients require attention and assistance from their caregivers on a daily 
basis. An integrative4 review from 2012, reviewed the literature on nursing staff, 
quality of care and QoL. They found that higher nursing staff affected the residents’ 
outcomes in a positive way and concluded that more nursing staff is required to reach 
optimal QoL for NH residents (Shin and Bae, 2012). Many of the studies in the 
review were observational, so a causal relationship cannot be stated. Another finding 
in the literature is that formal caregivers’ time with NH residents are associated with 
better health outcomes, like fewer pressure ulcers (Horn et al., 2005). Since negative 
health outcomes are associated with poorer QoL, more time use can thus increase 
patients’ QoL. To my knowledge, there is little research investigating the causal 
relationship between time use and QoL in NH patients with dementia, and the causal 
association is yet not clear. 
 
 
                                      
4 The main difference between a systematic review and an integrative review is the types of studies 
that are included in the review. Integrative reviews include both quantitative and qualitative studies, 




3.2.2 Informal Care 
Patients suffering from dementia are often taken care of by their family, friends and 
relatives. This is called informal care and is most commonly referred to when the 
caretaker is not residing in a long-term care institution. Even so, a Dutch cross-
sectional study by Metzelthin et al. (2017) found that informal caregiving does not 
stop with the admission to a NH. Informal caregivers provide an important role in 
the NH environment, and often perform tasks similar to those performed when the 
patients is residing at home, including feeding, grooming, and providing 
transportation (Schulz et al., 2014). Informal caregivers have also been found to have 
an active role in caring activities, such as social group activities (e.g. bridge-club), 
providing coffee and tea, meal activities, cleaning and reacting to incidents (e.g. 
aggressive behavior towards other residents or staff) (Paulus et al., 2005). 
Opportunity cost 
Informal care often comes with an opportunity cost, which can be defined as the 
caregiver’s foregone benefits due to time spent on providing informal care (Berg et 
al., 2004). There is an opportunity cost also for informal caregivers with a relative in 
the NH. A study by (Gautun and Bratt, 2017), investigated how public health 
services (NHs) affect the work attendance of adults with parents in need in Norway. 
Only adults with one parent alive were included, because a spouse could take on 
much of the care responsibility. The findings suggest that when the parent is residing 
in a NH, absence from work is lower, compared to if the parent is not in a NH. This 
further indicates that although less than if the parent is not residing in a NH, there 
still exists an opportunity cost for adults with parents living in NHs. The data are 
cross-sectional. Thus, the causal relationship is not identified in this study. 
Another source of opportunity costs of informal care can be related to that the care-
tasks lead to negative consequences for the caregivers. Caring for a loved one can 
make caregivers in both home-caring and institutions experience a high burden of 
care (Metzelthin et al., 2017). In this cross-sectional study, the researchers considered 
both objective burden (provided caregiving hours) and subjective burden (self-rated 
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burden scale). They found that even though the informal caregivers in 
institutionalized long-term care provided significantly less caregiving hours, they 
experienced a comparable level of subjective burden to caregivers living with the 
patient at home. This implies that the subjective burden the next of kin can 
experience, is not lifted when the patient is admitted to a NH. In their sample, most 
of the informal caregivers in institutionalized long-term care were adult children 
caring for their parents. Due to the study design, we cannot interpret this as a causal 
conclusion.  
3.2.3 Psychotropic drugs 
Neuropsychiatric symptoms are commonly seen in people with dementia and include 
behavioral and psychological symptoms such as agitation, irritability, aggression, 
apathy, and hallucinations (Quinn, 2013). In a Norwegian cross-sectional study, 
Selbæk et al. (2007) found that 89 % of individuals diagnosed with dementia 
exhibited a neuropsychiatric symptom the past week.  
Psychotropic Drugs and Dementia 
Neuropsychiatric symptoms in NH patients with dementia are often treated with 
psychotropic drugs, like antipsychotics and antidepressants. This is also the case in 
Norwegian NHs, where around 75 % of the residents receive one or more psychotropic 
drugs (Selbæk et al., 2007). It is found that one of three NH residents uses at least 
one unnecessary drug, and that many elderly use psychotropic medication that is 
unrecommended for use in the elderly (Ministry of Health and Care Services, 2015). 
Despite the widespread use, the effect of these drugs is debatable, where some find 
modest effects, and yet others find no effect (Sink et al., 2005, Ford, 2015). This 
excess use can lead to higher costs due to the patient’s increased risk of hospital 
admission when on psychotropic medication. A large nationwide observational study 
based on register data of the general population of elderly in Sweden, found that 
psychotropic drug use, particularly when combined, is associated with higher risk of 
hospitalizations, with dementia as a predictor (Johnell et al., 2017). 
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Psychotropic Drugs and QoL 
The use of psychotropic drugs in elderly NH patients with dementia is not 
unproblematic, however. According to Gurwitz et al. (2017, p.118), the “excessive use 
of antipsychotic drugs among long-term nursing home residents with dementia has 
been among the most challenging issues in the care of this vulnerable population”. 
Psychotropic drugs have been linked to various negative effects in elderly people, 
such as increased risk of mortality (Gill et al., 2007), increased risk of seizures 
(Bloechliger et al., 2015) and increased risk of falling (Cox et al., 2016). It has been 
found that NH residents with dementia tolerates discontinuation (Helvik et al., 2017), 
which indicates that patients can safely decrease the risk of side-effects, by taking less 
of these drugs. From this, one can conclude that psychotropic medication can affect 
elderly people’s QoL. For instance, consequences from a fall can be a bone fracture or 
head injury, which can drastically reduce the patient’s QoL. Some studies suggests 
that psychotropic medication negatively impacts QoL (Mjørud et al., 2014), while 
others find no such evidence (van de Ven-Vakhteeva et al., 2013). 
3.2.4 Drug or time use 
How to best use the resources in a NH is a continuous consideration for the decision-
makers and NH management. As seen, people with dementia often have 
neuropsychiatric symptoms. Managing such behaviors can be very challenging for NH 
staff, especially those providing direct care (Galik et al., 2014). A common such 
symptom is agitation. Agitation includes restlessness, aggression, and excess motor 
activity, and is associated with excess staff burden (Rinaldi et al., 2005, Aronson et 
al., 1993, Sourial et al., 2001). How to best handle agitated patients can lead to the 
question if one should medicate or hire an extra caregiver. Should medication be used 
as a means of behavior control, or should a caregiver try to calm the patient with 
individualized care? Both alternatives can lead to the same goal, which can be to 
calm the patient and make sure he is not negatively interacting with other patients. 
Which input is chosen will affect the costs differently, depending on if the perspective 
of the patient, society or NH management is taken. Medicine (capital) is cheaper 
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than labor, and if the former is chosen the cost will be lower for the NH and society. 
On the other hand, it can also result in costs for the patient and society, in form of 
negative side-effects and increased hospitalization. A longitudinal study from 2017 by 
Helvik et al. (2017), shows high prevalence and persistence of psychotropic drugs in 
Norwegian NHs. This can indicate that the cheapest alternative, namely drugs, are 
often chosen in order to address neuropsychiatric symptoms often seen in people with 
dementia. This can be due to the economic gain, convenience, lack of staffing or 
knowledge, or that medication use is unsystematically reviewed, or not reviewed at 
all. 
In the query of using drugs or time, to for instance calm the patient, a question is 
how these two resources work together or depend on each other. Specifically, there is 
the question if they work as substitutes in a NH setting. To the best of my 
knowledge, there is no literature investigating whether psychotropic drugs work as a 
substitute for formal care, or vice versa, in the NH. Still, some studies indicate that 
this can be the case, or that they at least depend on each other to some degree. 
Perhaps the most common hypothesis on the relationship between formal care and 
psychotropic medication, is that better staffing will lead to lower rates of drug use 
(Schmidt et al., 1998). Using an instrumental variables method on longitudinal data, 
Cawley et al. (2006) found that higher wages for NH workers increased the use of 
psychotropic medication, where higher wage was driven by reduced labor supply. 
Further, a study investigating the relationship of facility characteristics and use of 
psychotropic medication, found that the only significant factor correlated with 
excessive use was the level of staffing: Facilities with better staffing had less excessive 
use of psychotropic medication (Schmidt et al., 1998). A systematic review that 
investigated how staffing influences QoL and quality of care for long-term dementia 
care residents, found that more staff and more qualified staff, lead to less use of 
psychotropic medication (Anderson et al., 2016). Staff distress and less attention and 
care provided for the residents, were associated with greater reliance on psychotropic 
drugs. The studies investigating this are of observational design, and no causal 
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relationship can be concluded on. These findings indicate that when more staff is 
available, they cover the care needs to a higher degree than if less staff is available. 
When there are not enough staff, other non-staffing means, such as medication, must 
“step in” to cover the care needs. But we do not know if psychotropic drugs actually 
work as a substitute for formal care, and if so, to what degree.  
4. Data 
The COSMOS-data was collected in 2015-2016 on behalf of Centre for Elderly and 
Nursing Home Medicine (SEFAS), University of Bergen (UiB). COSMOS is a 
longitudinal study with panel data on NH patients for three points in time, stretching 
for nine months. This chapter explains the COSMOS-study and the sample data in 
more detail.  
4.1 The COSMOS-study 
COSMOS is an acronym for Communication, Systematic assessment and treatment of 
pain, Medication review, Occupational therapy, and Safety (COSMOS). The overall 
objective is to improve QoL in NH patients. The COSMOS-program is based on 
evidence from the literature, and the research groups’ own scientific and clinical 
experiences. The intervention aims to improve the physical and mental health of the 
patients, increase safety and cost-effectiveness, and reduce unnecessary hospital 
admissions and medication. The researchers want to achieve their goal by educating 
NH staff in: 
i. enhanced communication and advance care planning 
ii. organizing meaningful activities 
iii. medication reviews 
iv. systematic assessment and treatment of pain (Husebo et al., 2015) 
This thesis uses a selection of the COSMOS-sample, because only people with 
dementia are considered. In the COSMOS-study they also used multiple instruments 
to measure QoL, while in this thesis only one is considered. Therefore, my data is 
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different from the COSMOS-data and my findings will not apply to the COSMOS-
study as a whole. 
2.1 Method and Design 
The COSMOS-study includes a two-month pilot study, with 128 NH patients 
distributed among nine Norwegian NHs, and a four-month multicenter, cluster 
randomized effectiveness-implementation clinical hybrid trial, with follow-up at 
month nine (Husebo et al., 2015). The COSMOS-intervention involves 765 patients 
from 71 NH wards (Aasmul et al., 2018). The inclusion criteria were (i) NH patients 
with and without dementia (ii) 65 years or older. Patients were excluded if they were 
dying (life expectancy of 6 months or less) or had schizophrenia. In order to get a 
more representative sample, NH wards in various parts of Norway were included, 
where one NH ward is defined as one cluster5. The clusters were randomized to either 
the control or intervention group, where the control groups continued with current 
best practice. The cluster design will take account of spill-over effects and the fact 
that people living and working in the same unit are more similar in the first place 
(e.g. they have the same health personnel/colleagues and environment) (Husebo et 
al., 2015). 
The COSMOS-intervention is complex and comprehensive and includes many NHs 
and different health personnel. Complex interventions can lead to ineffective 
implementation, and it was thus important to test and improve the implementation 
during the investigation. According to Craig et al. (2008), a lack of impact can be due 
to implementation failure, rather than ineffectiveness, which makes it necessary to 
evaluate the process to identify possible problems connected to the implementation. 
In other words, poor implementation could be the reason for a possible unobserved 
effect. There was continuous surveillance of the implementation process with 
telephone calls, visits, and more. The COSMOS-study used a mixed method study 
                                      
5 The definition of clusters was later changed. This is further elaborated in section 5.1.1. 
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design to cover the whole process of implementation and assessment of the 
intervention (Husebo et al., 2015).  
2.2 Intervention and Implementation 
The implementation happened between baseline and 4-month follow-up and had two 
stages. First, health personnel such as nurses, NH managers, licensed practical nurses 
or physicians from each NH unit participated in a two-day seminar, where they were 
educated on COSMOS implementation domains (activity, pain assessment, 
communication, medication review and safety). The seminar included written 
guidelines, case discussions, repeated theoretical and practical training, and role play. 
Nurses attending the seminar became the COSMOS-ambassadors (Aasmul et al., 
2018). Second, the ambassadors implemented the intervention in the NH wards by 
educating and informing their colleagues, if possible multiple times a week. Each week 
the focus was on one of the implementation domains mentioned above. Additionally, 
a midway one-day evaluation, regular telephone calls, and a telephone hotline where 
NH staff could reach out if they had a concrete question related to data collection or 
internal education was offered to the intervention group. Medication reviews were 
completed in collaboration between the NH physician, NH staff and two COSMOS-
researchers. The control group received care as usual and was monitored by telephone 
contact on a monthly basis. To motivate the control group to continue participating, 
they received the COSMOS-intervention after month 9 (Husebo et al., 2015). 
2.3 Outcomes 
The primary outcome in COSMOS is QoL in NH patients and secondary outcome 
measures include neuropsychiatric symptoms (NPS), pain, activities of daily living 
(ADL), sleep, depression, hospital admission, medication, communication, staff 
distress and mortality measured at baseline, and 4- and 9-month follow-up (Husebo 
et al., 2015).  
4.2 The sample data 
4.2.1 Assessment of the variables 
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Dementia was assessed with the Mini Mental Status Examination (MMSE) 
questionnaire, a tool to assess cognitive status. It contains 20 questions, including the 
categories orientation in time, orientation in place, immediate recalling/recognition, 
repetition, apprehension, reading, and writing/generating sentences. Low score 
indicates low cognitive status, while a high score indicates high cognitive status 
(Strobel and Engedal, 2008). In my analysis, the cut-of score for identifying NH 
patients with dementia was a MMSE total score < 25, which identifies mild to 
severely cognitively impaired patients. This complies with the Norwegian MMSE 
manual (Strobel and Engedal, 2008) and the COSMOS-study (Husebo et al., 2015).  
The instrument Quality of Life in late-stage Dementia (QUALID) was developed by 
Weiner et al. (2000) to assess QoL in people with late-stage dementia residing in 
long-term care facilities. As late-stage dementia patients have difficulty expressing 
themselves, a proxy rate is necessary. With QUALID, QoL is assessed by next of kin 
or health personnel that deal with the patient on a daily basis, and should be 
considered on the basis of concrete, observable behavior and emotional expressions of 
the patient. It is an 11-item, 5-point scale, with a total score range of 11-55, where 
lower score indicates higher QoL. The Norwegian version has been validated and is 
perceived as reliable (Røen et al., 2015). 
The form Resource Utilization in Dementia – Formal Care (RUD-FOCA) was 
developed to serve as a standardized tool to measure the direct care time required in 
the nursing home. It measures direct care time spent the last four weeks, in the three 
categories activities of daily living (ADL), instrumental ADL (IADL), and 
supervision, for both formal- and informal caregivers. ADL includes care tasks like 
toileting, bathing, hygiene, and eating, which I have chosen to call “general care”. 
IADL includes care tasks like taking medicine, go to the hairdresser, and doing 
administrative tasks, which I call “everyday tasks”. Direct care time includes for 
example the time a health personnel spends on helping a wandering patient back to 
his room, but not time spent in a quiet ward (Luttenberger and Graessel, 2010). 
According to Luttenberger and Graessel (2010), RUD-FOCA is validated as a 
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suitable instrument for recording the direct care time in NHs, even though IADL 
needs improvement. In my thesis, time use will be the direct care time for each 
patient in the last month, measured in hours. 
There are different ways of defining psychotropic drugs. I have defined psychotropic 
drugs as the psychoactive drugs: antipsychotics, antidepressants, anxiolytics, 
hypnotic/sedatives, and anti-dementia, which is in accordance with earlier studies 
(Røen et al., 2017, Helvik et al., 2017). My thesis does not take dosage or length of 
prescription into account, because it is outside the scope of this text. 
4.2.2 Weaknesses 
The sample are people with dementia. This leads to much of the data collected being 
secondhand-information, because many of the forms are not filled out by the patients 
themselves, but the responsible caregiver. This can be problematic because it has 
been found differences between what the patient reports and what the next-of-kin or 
health personnel reports when filling out forms regarding QoL (Sloane et al., 2005).  
The intervention is measured only over nine months. If the patients were followed for 
a longer period of time, more information could be collected, and more precise 
estimates could be found. To follow the individuals until death, would be ideal. 
However, there are resource constraints that must be considered.  
Further, there was no information collected regarding how much the health personnel 
learned throughout the intervention. So, there was no quantifying measure of how 
successful the implementation of the intervention was. Advantageously, this could be 
collected shortly after the intervention, to get information on to what degree the 
health personnel’s knowledge increased. If the health personnel did not increase their 
knowledge, or only slightly, one could maybe not expect an effect of the intervention 
either. 
4.2.3 Strengths 
The data are longitudinal, and not observational. This means that we follow the same 
individual over time, which enables us to uncover causal relationships, and not just 
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associations. This is important because we want to know what the intervention 
causes, and not just what it is associated with. In an observational study, it is 
possible that other factors not accounted for causes the outcome. This is what we are 
trying to get around by using longitudinal data. The randomized control and 
intervention groups also makes it possible to identify the causal effect of the 
intervention. 
When studying elderly people with dementia, many patients often die during the 
study period because of their frail health condition and old age, or they move. In my 
sample, no patient died or moved during the three data-collection periods in neither 
of the groups. That the sample is made up of the same patients during the whole 
study is a strength, since we know that the same people are compared before and 
after the intervention is implemented. We also know that a change in one of the 
outcome measures cannot be due to many people dying; for example, if QoL is 
increasing from month four to month nine, we know that it is not because patients 
with poor health and QoL died in-between data collection in months 4 and 9.  
4.2.4 Missing values 
In a study with many questionnaires, missing values is difficult to avoid. Proxy-raters 
can have trouble knowing what to answer or can be occupied with care duties in the 
middle of the procedure, and thus forget to fill in the appropriate answer. How to 
treat missing values, is a large and complicated field. My approach is to exclude all 
patients with missing values in variables used in the sample selection process, e.g. the 
measure for QoL and cognition. This was chosen because inclusion of patients with 
missing values could have led to incorrect inclusion of patients. An example can be 
derived from the process of identifying people with dementia. If patients with missing 
values were to be included while calculating total MMSE-scores, this could have 
overestimated the number of people with lower cognitive status: if a patient with a 
missing value had a score of 24, this missing value could give a point if filled out 
properly and thus make this patient actually go over the cut-off score. If this is the 
case, the patient is falsely included in the study. To ensure that only correctly 
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specified patients are included, all patients with an MMSE missing value are excluded 
from the study. It was only necessary to exclude patients with missing MMSE values 
in the baseline data, since the baseline score was used to identify the level of 
cognition. Also, patients with missing values in outcome variables were excluded. 
This was chosen so that the same patients were compared in all model specifications. 
There are missing data in the other measurement variables as well, but these can be 
believed to be missing at random: If the proxy-rater was interrupted, e.g. due to 
sudden care duties, in the middle of the procedure of filling out the questionnaire 
which then led to missing values, it is likely that the interruptions happened at 
random. Regarding how raters can have difficulties answering certain questions, this 
is more likely non-random and could lead to selection bias. To exemplify, take for 
instance the measurement of QoL. If the raters consistently find it difficult to answer 
if the patient has low QoL, but not high QoL, there would be much missing data 
when a patient has low QoL. This can further lead to little information about 
patients with low QoL, and the estimation of change of QoL over time can be biased. 
5. Method 
This chapter describes the method used in detail. The advantages of randomized 
controlled trials and randomization are discussed, but it is also questioned whether 
randomization is enough for drawing causal conclusions. Further, the descriptive 
statistics at baseline gives an insight into the successfulness of the randomization. To 
estimate the average treatment effect on the treated on the outcome variables, the 
chosen estimation strategy is a fixed effects regression model.  
5.1 Randomized controlled trials 
A randomized trial studies a sample of people from the same underlying population. 
A certain treatment is given to a randomly chosen subset of these people, and the 
rest carry on without (or with only partly) treatment. The key is the random 
assignment, making the comparison of groups ceteris paribus: the only difference 
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between them is the treatment status (Angrist and Pischke, 2015). In the COSMOS-
study, the treatment was the COSMOS-intervention, and the control group carried 
on with care as usual. Wards, and not individuals, were randomized due to a high 
probability of spill-over effects if randomization was performed on an individual level. 
The NH wards in each municipality were randomized after they were recruited. NHs 
in the municipalities Sund, Kvam, Fjell and Øygarden were recruited and then the 
NH wards here were randomized. The same process was then repeated in Bærum, 
Sarpsborg, and Bergen. This ensured that the intervention and control group 
contained an equal number of wards that are considered rich/poor and rural/urban. 
This makes the two groups more similar to each other before the experiment begins 
and can minimize the random error due to systematic differences, and increase the 
internal validity. To ensure randomness, ideally, all NHs should be recruited and then 
randomized, but due to budgetary reasons and time-constraints the process described 
above was chosen. 
Two randomly chosen groups are similar, as long as the sample is large enough. This 
is due to the powerful statistical property Law of Large Numbers (LLN), stating that 
a sample average can be brought close to the population average, simply by enlarging 
the sample. This ensures that systematic differences due to, for instance, individual 
characteristics like gender, will wash out (Angrist and Pischke, 2015). If a variable 𝑌𝑖 
is generated through a random process, like the throw of a die, the population 
average 𝐸[𝑌𝑖] is the average if this process is repeated infinitely. 𝐸[𝑌𝑖] is called the 
mathematical expectation of 𝑌𝑖. If 𝑌𝑖 comes from a sample survey, 𝐸[𝑌𝑖] represents the 
average obtained if every person in the population from which the sample was drawn 
were included (Angrist and Pischke, 2015). In my sample, there are 154 people in the 
treatment group and 120 people in the control group. This is not a large sample size, 
and it can be questioned whether the property of LLN will be put into effect.   
5.1.1 Is randomization enough? 
Perfect randomization is difficult to achieve. Random samples are not perfect 
samples, and there will always be sample errors (Mitchell and Jolley, 2012). 
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Randomization done on an entire population, would be very reliable, as the group 
studied would both be very large and representative. Unfortunately, this is not 
possible, and randomization must be done on a smaller sample of the population. The 
sample might not always be a good representation of the population, especially so for 
smaller samples. For example, it can by chance be older or generally sicker than the 
population. This leads to systematic bias despite randomization.  
This is further elaborated with inspiration from Mastering ‘Metrics by Angrist and 
Pischke (2015). Let 𝑌 represent the outcome. To distinguish between the individuals 
in the control and intervention group, let 𝑌0𝑖 denote the outcome if individual 𝑖 is in 
the control group, and 𝑌1𝑖 if he is in the intervention group. The difference in the 
outcome averages without randomization can be written as: 
Difference in group means = Average causal effect + Selection bias 
Selection bias is here the difference in average 𝑌0𝑖 between the intervention and 
control group. In other words, the difference between the two groups in the outcome 
variables that would have been there even without treatment, because the difference 
was present before treatment. With random assignment on the other hand, we expect 
the two groups to be equal in both what can be observed, and what cannot be 
observed due to the random assignment process. Let 𝐷𝑖 denote treatment. If 
treatment is randomly assigned, 𝐸[𝑌0𝑖|𝐷𝑖 = 1] = 𝐸[𝑌0𝑖|𝐷𝑖 = 0], and the expected 
outcome for individual 𝑖 when not treated would be the same regardless of which 
group the individual belongs to. Then the differences in expectations by treatment 
status captures the causal treatment effect 𝜅: 
 
𝐸[𝑌𝑖|𝐷𝑖 = 1] − 𝐸[𝑌𝑖|𝐷𝑖 = 0] 
= 𝐸[𝑌1𝑖|𝐷𝑖 = 1] − 𝐸[𝑌0𝑖|𝐷𝑖 = 0] 
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= 𝐸[𝑌0𝑖 + 𝜅|𝐷𝑖 = 1]6 − 𝐸[𝑌0𝑖|𝐷𝑖 = 0] 
= 𝜅 + 𝐸[𝑌0𝑖|𝐷𝑖 = 1] − 𝐸[𝑌0𝑖|𝐷𝑖 = 0] 
= 𝜅 
Thus, a successful random assignment can eliminate selection bias, and uncover the 
causal effect – as long as the sample is large enough for the LLN to kick in. This 
process does not eliminate individual differences, but makes sure that the mix of 
individuals are equal in both groups (Angrist and Pischke, 2015). In my thesis, wards 
have been randomized, not individuals. Therefore, we expect the individuals to be 
equal on average across the wards in the two groups. Even though random 
assignment can eliminate selection bias, it does not ensure that all selection bias is 
eliminated. Though intuitive in theory, in practice it can be very difficult to ensure 
that the control and intervention group are very similar, that the observed effects are 
generalizable and that the effects are a function of only the intervention itself 
(Khandker et al., 2010). In my sample, there are some problems challenging the 
randomization. One problem, already mentioned, is that my sample is small, and 
hence that it is questionable if the properties of the LLN kicks in. 
Another challenge is that the control group received information about the content 
and aim of the COSMOS-intervention. This was part of each NH’s process of 
deciding whether they wanted to participate or not. And after randomization, as part 
of the data collection, the control group staff also filled out and was trained in the 
various questionnaires used in the study (Husebo et al., 2015). Therefore, the control 
group can have gotten the equivalent of “partial treatment”, even though they should 
have continued with care as usual. The researchers in the COSMOS-study are aware 
of this, and state that “the control group may also derive a considerable learning 
effect” (Husebo et al., 2015, p.5). 
                                      
6 𝑌1𝑖 = 𝑌0𝑖 + 𝜅 , or 
6 𝑌1𝑖 − 𝑌0𝑖 = 𝜅 because the difference between the outcome when treated (𝑌1𝑖) and 
the outcome when not treated (𝑌0𝑖) is the constant effect of the treatment 𝜅. This is called the 
constant-effect assumption. If treatment is randomized, 𝜅 is the causal effect of treatment.    
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The control and intervention groups can be located in the same NH, since the 
randomization is performed on a NH ward level. Further, the same staff could work 
in both intervention and control wards. This is related to the definition of a ward 
being different between the NHs; in one NH a ward could include three groups or 
corridors, while this would be three separate wards at another NH. Therefore, a 
unifying definition of a ward was made, stating that a ward consists of patients 
sharing kitchen and living room. These factors can have led to spill-over effects on 
the control group. 
Lastly, the researchers cannot force anyone to take the treatment or not, which 
basically means that the researcher have a lack of control. Randomizing a sample 
into treatment and control groups, does not ensure that everybody in the treatment 
group gets treatment, nor that nobody is treated in the control group. After being 
assigned to one group, the participant can refuse to participate, or try to get the 
other treatment some other way. In the COSMOS-study, the control group was 
offered the intervention nine months after they were invited to participate, since the 
control condition was “care as usual”. This can have led more NH wards assigned to 
control to withdraw from participation, than NH wards assigned to intervention. On 
the other hand, it could also ensure and encourage the NH wards to join the 
intervention, since they were ensured to get the intervention later. Further, there is 
no way of making sure that the people in the intervention wards actually did what 
they were supposed to when the researchers or COSMOS-ambassadors were not 
there. 
So, random samples are not perfect, and validation of the data and randomization 
must be performed. The first and most important thing to do, is to perform a balance 
test on the baseline data. 
5.2 Descriptive statistics 
5.2.1 Balance tests 
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It is reasonable to believe that the outcome variables are affected both by who you 
are as a person and which ward you are placed in. There can be systematic 
differences between the wards and individuals in the control and intervention group, 
which could be present before the intervention. This implies that a potential 
difference observed after the intervention would have been observed also without the 
intervention. Hence, it is important to detect differences between the control and 
intervention group before treatment on both the individual- and ward level. Thus, we 
must perform a balance test on the baseline data. The balance checks should show 
non-significant results to support a successful randomization. This further supports 
that the patients in the two groups are similar in both observed and unobserved 
differences. For this cause, the t-test has been calculated for the various variables. In 
Table 2 the patient descriptive statistics are displayed, and in Table 3 the ward 
descriptive statistics can be seen. 
 
Table 2 Patient: Descriptive Statistics at Baseline 
  Intervention  Control  Difference  
 Scale Mean sd Mean sd p-value t-value 
Demographics and health        
        
Age year 86.64 (7.11) 86.55 (7.28) 0.916 -0.11 
        
Men proportion 0.26 (0.44) 0.23 (0.42) 0.509 -0.66 
        
Married proportion 0.27 (0.44) 0.19 (0.40) 0.149 -1.45 
        
Weight kg 64.80 (14.24) 63.89 (13.41) 0.603 -0.52 
        
Height m 1.64 (0.10) 1.64 (0.09) 0.832 0.21 
        
Blood pressure  129.55 (21.09) 125.05 (19.89) 0.085 -1.73 
        
Blood pressure  72.14 (11.24) 71.15 (11.81) 0.496 -0.68 
        
Pulse  71.91 (12.23) 72.84 (13.23) 0.565 0.58 
        
Scores from COSMOS-study        
        
Formal care (RUD-FOCA) hrs/month 49.32 (48.88) 52.64 (46.83) 0.571 0.57 
        
ADL  32.50 (25.67) 33.39 (27.48) 0.783 0.28 
        
IADL  9.16 (14.79) 10.72 (12.40) 0.356 0.93 
        
Supervision  7.66 (25.87) 8.53 (16.44) 0.748 0.32 
        
Informal care (RUD-FOCA) hrs/month 4.16 (14.01) 2.21 (6.66) 0.162 -1.40 
        
ADL  1.48 (6.10) 0.64 (2.80) 0.160 -1.41 
        
IADL  1.82 (7.69) 1.17 (3.93) 0.397 -0.85 
        
Supervision  0.85 (3.79) 0.41 (2.36) 0.262 -1.12 
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QoL-score (QUALID) 11-55 20.99 (7.39) 21.13 (7.46) 0.884 0.15 
        
Cognitive status (MMSE) 0-30 10.32 (6.67) 11.45 (7.19) 0.182 1.34 
        
Pain-score (MOBID) 0-10 2.32 (2.47) 2.55 (2.76) 0.499 0.68 
        
Agitation-score (CMAI) 29-203 41.77 (16.15) 42.03 (14.82) 0.893 0.14 
        
Activities-of-daily-living-score 0-30 20.00 (11.04) 20.12 (12.00) 0.933 0.08 
        
Depression-score 0-38 6.74 (5.96) 6.96 (5.74) 0.779 0.28 
        
Neuropsychiatric symptoms-score 0-120 14.62 (17.26) 14.05 (17.95) 0.798 -0.26 
        
Caregiver distress-score 0-50 7.77 (7.12) 7.24 (8.28) 0.606 -0.52 
        
Psychotropic drug use        
        
Antipsychotics n 0.18 (0.45) 0.14 (0.42) 0.449 -0.76 
        
Anxiolytics n 0.18 (0.39) 0.26 (0.54) 0.174 1.36 
        
Hypnotics and sedatives n 0.27 (0.46) 0.40 (0.59) 0.045* 2.01 
        
Antidepressants n 0.44 (0.60) 0.48 (0.56) 0.500 0.67 
        
Anti-dementia drugs n 0.16 (0.39) 0.13 (0.34) 0.518 -0.65 
        
Total drug use n 1.23 (1.12) 1.42 (1.19) 0.193 1.30 
N  154  120  274  
* p<0.05, ** p<0.01, *** p<0.001 
Notes: The table shows the t-statistics of mean differences in the intervention and control group for different patient characteristics and scores at 
baseline. Standard deviations in parentheses. 
 
 
As we can see in Table 2, patients in the control and intervention groups are quite 
similar, and there are mostly non-significant differences. Blood pressure and use of 
hypnotics and sedatives are significantly different on a 0.05 % and 0.10 % significance 
level, respectively. But in a table with many comparisons, a few isolated differences 
that are statistically significant are often also likely to chance (Angrist and Pischke, 
2015). The patients are on average 86 years old, in other words a relatively old 
sample, and most of the patients are female (approximately 75 %) and not married or 
widowers (approximately 75 %). The average MMSE-score is around 11, which tells 
us that many of the patients in the sample has a far-advanced type of dementia. 
Most of the patients do not give the formal caregivers a large care burden, but are 
highly dependent in ADL-tasks as most of the formal time use is spent here. On 
average, the patients receive little informal care. Something worth noticing is that 
informal care, and to a smaller degree, formal care, psychotropic medication and 
some other variables, had different baseline levels. Even though the differences were 
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non-statistical, a problem could be that if the sample size increased, the differences 
could diverge and become significantly different. 
Table 3 Ward: Descriptive Statistics at Baseline 
  Intervention  Control  Difference 
 Scale Mean sd Mean sd p-value t-value 
Patients n 15.59 (6.88) 18.05 (8.42) 0.267 1.12 
        
Staff, daytime n 5.07 (2.21) 5.91 (2.41) 0.212 1.26 
        
Staff, evening n 3.63 (2.06) 3.66 (0.97) 0.951 0.06 
        
Staff, nighttime n 1.40 (0.65) 1.47 (0.66) 0.717 0.36 
        
Weekend: Staff, daytime n 4.21 (2.17) 4.55 (1.44) 0.537 0.62 
        
Weekend: Staff, evening n 3.62 (2.07) 3.61 (0.98) 0.986 -0.02 
        
Weekend: Staff, nighttime n 1.36 (0.62) 1.47 (0.66) 0.549 0.60 
        
Doctoral visits, per week hours 6.63 (6.39) 6.43 (7.80) 0.926 -0.09 
        
Total staff n 22.35 (10.94) 24.48 (9.19) 0.478 0.71 
        
Registered nurses n 5.31 (2.82) 5.77 (2.18) 0.535 0.62 
        
Assistant nurses n 10.93 (6.33) 11.33 (4.76) 0.807 0.25 
        
Unskilled nurses n 5.85 (4.81) 7.00 (4.63) 0.402 0.85 
        
N  27  22  49 
* p<0.05, ** p<0.01, *** p<0.001 
Notes: This table shows the t-statistics of the mean differences between NH ward characteristics in the control and intervention 
group. Standard deviations in parentheses. 
 
The ward descriptive statistics are non-significant, and we can see that the two 
groups are quite similar on the ward level. In general, there are more intervention 
wards than control wards. The wards in the intervention group are on average 
smaller, which is probably why there are systematically less staff here compared to 
the control group. Six of the wards are not included in the descriptive statistics due 
to missing values, where most misses all information.  
There was also information on the wards’ access to different personnel. The 
differences are mostly non-significant, though one (access to social workers) came up 
as statistically significant. The table can be found in Appendix 1. An interesting 
finding is that around 60 % of the wards have access to volunteers, while none of the 
wards in the intervention group, and only 15 % of the wards in the control group, 
29 
 
have access to a social worker. This indicates that social and other activities are 
mostly driven by the staff or volunteers like next-of-kin or volunteering organizations. 
Despite the small sample size, the intervention and control groups are quite similar, 
which supports that randomization was successful.  
5.2.2 Distributions 
Even though the average values in the groups are similar in most variables, the 
underlying distributions can be different. By looking at the distributions, one can 
inspect for worrisome differences, and other potential problems, like outliers, and 
evaluate if this needs to be considered in the analyses or discussion. This section 
discusses the dependent variables’ distributions, which can be found in Appendix 2. 
For formal care, the distributions are largely skewed to the left, with few relatively 
high time-consuming patients. In the intervention group there are a few more highly 
time-consuming individuals. In the control group, the distribution peaks at around 50 
hours per month, while the peak in the intervention group are a little less than 50 
hours. In general, the two groups have a relatively equal spread of observations. The 
distributions for informal care are also relatively equal. There are some patients in 
the intervention group that receive a very high amount of informal care compared to 
the others (between 50 and 90 hours per month), which can explain why the average 
of informal care is higher in the intervention group compared to the control group. 
But most patients receive little or no informal care. Also for QoL, the distributions 
are relatively similar and skewed to the left. Since the QoL instrument, QUALID, 
uses a scale where a low score means higher QoL, this means that the majority of 
patients have a relatively high QoL. The distributions of psychotropic medication are 
fairly similar for both intervention and control group. They are skewed to the left, 
with between 20 % and 30 % of the patients taking no psychotropic medication in 
both groups. The highest percentage (approximately 35 %) of patients in both groups 
use one psychotropic drug. Less than 15 % in the control group and 10 % in the 
intervention group takes three or more different psychotropic medications. 
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5.3 The road to causality  
5.3.1 Impact evaluation 
This section is largely inspired by Khandker et al. (2010). In order to say something 
about how successful an intervention is, we want to uncover causal effects. This 
means to isolate the effect that is caused by the intervention, which would not have 
been there without it. Ideally, we want individual 𝑖 to both get the intervention, and 
not get the intervention. Afterwards, we would subtract the differences in outcome 
and get the causal effect of treatment. Of course, this is not possible, since at a 
particular point in time, a person cannot both get treated or not treated. To get an 
approximation of the unobserved counterfactual outcome, we can estimate it. One 
way to do this by replacing the counterfactual outcome with a control group that has 
not been given the treatment.  
We want to estimate the average treatment effect on the treated (ATET). Let there 
be two periods, one period before treatment (0) and one after (1). All individuals 
either get treated (D=1) or not treated (D=0). Outcome when treated is 𝑌1, while 
outcome when not treated is 𝑌0. Then we want to estimate 
𝛼𝐴𝑇𝐸𝑇 = 𝐸[𝑌1(1) − 𝑌0(1)|𝐷 = 1] 
This is an estimate for the difference in the outcome if treated and the outcome if not 
treated for the individuals in the intervention group. 𝑌0(1)|𝐷 = 1 is the 
counterfactual and unobservable outcome, and what we want to estimate. When 
individuals are successfully randomized to control and intervention groups, they are 
expected to be equal in every way, both in observed and unobserved factors. If this 
assumption holds, the outcome for the randomized non-treated patients is a good 
measure of the counterfactual outcome for the treated, and 𝑌0(1)|𝐷 = 0 is a valid 
counterfactual estimate of the outcome 𝑌0(1)|𝐷 = 1. A successful randomization leads 
to the observed outcomes in the control group being a counterfactual outcome for the 
intervention group if they did not get the COSMOS-intervention. When the groups 
are similar before treatment, if not for the treatment, they should also be similar in 
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the post-treatment period. A possible difference after treatment, will thus be due to 
the intervention.  
5.3.2 COSMOS: Possible factors challenging the causality 
As we have seen, a successful randomization of treatment to NH wards says that any 
differences in the average treatment effect between the treatment and control group 
are likely due to the COSMOS-intervention. This if further supported when the 
balance checks on both individual- and ward-level at baseline passed as mainly non-
significant. However, perfect randomization and zero selection bias is difficult to 
achieve. Presented below are some factors in the COSMOS-study challenging the 
causality.  
Firstly, the intervention was always implemented in the NH wards by different 
COSMOS-ambassadors. Therefore, it was not possible to control exactly how the 
implementation was given in each ward, and whether it was identically implemented. 
For example, there could be differences in how many days a week education in the 
COSMOS components (pain, medication review etc.) would be given to the colleagues 
by the ambassadors, and thereby differences in education thoroughness or focus. 
These implementation differences can impact which focus a ward has, and thus 
explain some of the differences we see between the intervention wards. Secondly, the 
participants couldn’t be completely blinded regarding which group they were 
allocated to because of the hybrid trial design, which allows for optimization during 
the process of intervention, education, and follow-up (Husebo et al., 2015). This can 
produce bias in the effect of the intervention, since people can respond (consciously or 
subconsciously) differently to the treatment if they think or know they are getting 
treated versus not getting treated. This can be due to e.g. preexisting expectations on 
the treatment’s effect (Schulz and Grimes, 2002). Another issue is the Hawthorne 
effect; that the health personnel change their behavior, either consciously or 
subconsciously, because they are being observed. People want to be perceived in the 
best way possible, and not seen as someone who is caring too little for the patients or 
do not spend enough time with them. Regardless, it was not possible to fully blind 
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the participants in this study. Thirdly, when participating in a study, people are not 
unbiased. The health care personnel probably want to see an effect and can more and 
less consciously try to affect the outcome in the desired direction. They may both 
want their patients to have a better QoL and also be part of something that made 
the patients feel better. So, during questionnaires in month 9, if they wish to see an 
effect, that is what they see, and record down.  
All these factors can challenge the causality and is something to bear in mind when 
interpreting the results. The next section describes how 𝛼𝐴𝑇𝐸𝑇 is estimated. 
5.4 Data analyses 
5.4.1 Panel Data 
The COSMOS-data are panel, or longitudinal, data. Each patient is measured at 
three different points in time, making it possible to follow each individual over time. 
The ability to observe the same patients over time is an advantage, since it permits 
controlling for certain unobserved characteristics of the individual. This makes 
causality more believable than if two cross-sectional units were compared 
(Wooldridge, 2014).  
5.4.2 Fixed Effects 
If the intervention and control group are successfully randomized, we can expect both 
observed and unobserved differences to be equal in the two groups on average. In 
addition to the factors challenging the randomization and causality, there are many 
factors I do not have data on in my sample, like education, diseases, or former 
hospital admissions. Thus, pre-treatment levels of these variables, and others, could 
not be checked for balance in the two groups. Therefore, fixed effects were included 
to further control for unobserved heterogeneity.  
The data are extracted from many different NHs and NH wards and places in 
Norway, and we can expect there to be fixed differences between the entities. These 
differences can explain some of the variance in the data collected. Differences can be 
due to the local socio-economic environment, geographical location, or the wellbeing 
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of staff and working environment on the various wards and NHs. Differences on an 
individual level can also be expected, such as education, income, pain tolerance, or 
general attitude towards life. The differences can be both observable and non-
observable, be constant or vary over time, and can affect our dependent variables 
(Wooldridge, 2014), independent of treatment status, and must be taken into account 
when performing regression analysis. The problem of just running a pooled ordinary 
least squared (OLS) regression on panel data, is that the results would be biased if a 
time-invariant factor 𝑎𝑖 (located in the error term 𝑢𝑖) is correlated with one or more 
of the independent variables. This would be a violation of the consistency of the OLS-
estimators, so that 𝑐𝑜𝑣(𝑢𝑖, 𝑥𝑖𝑡) ≠ 0, which is problematic. Examples of 𝑎𝑖 in the 
context of COSMOS can be chronic diseases or living location of closest relatives. 
To illustrate the fixed effect model, a model from Wooldridge (2014) is presented. 
Consider a model with a single explanatory variable:  
𝑦𝑖𝑡 = 𝛽0 + 𝛽1𝑥𝑖𝑡 + 𝑎𝑖 + 𝑢𝑖𝑡,       𝑡 = 1,2, … , 𝑇   [1] 
The notation i denotes the person, and t denotes the time period. The error term 𝑢𝑖𝑡, 
is often called the idiosyncratic or time-varying error, because it embodies the 
unobserved factors that are time-variant and affects the dependent variable 
(Wooldridge, 2014). 
If this equation is averaged over time within each individual, we get 
?̅?𝑖𝑡 = 𝛽0 + 𝛽1?̅?𝑖 + 𝑎𝑖 + ?̅?𝑖     [2] 




𝑡=1  , and so on. The variable 𝑎𝑖 captures all time-constant, 
unobserved factors that affects our dependent variable 𝑦𝑖𝑡, and is often referred to as 
a fixed effect, or individual effect. Because it is time-constant, 𝑎𝑖 will be the same in 
both equations. If we substract [2] from [1], we get 
?̃?𝑖𝑡 = 𝛽1?̃?𝑖𝑡 + ?̃?𝑖𝑡      [3] 
where ?̃?𝑖𝑡 = 𝑦𝑖𝑡 − ?̅?𝑖𝑡, and so on. [3] is called the time-demeaned data on 𝑦, 𝑥 and 𝑢. 
The method is called the fixed effects transformation or the within transformation. 
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The important thing to notice here, is that the unobserved effect 𝑎𝑖 has disappeared 
when the data was time-demeaned (Wooldridge, 2014). This means that we have 
gotten rid of all unobservable factors that do not change over time and could have 
been difficult to control for. An estimation of [3] will use the time variation in 𝑦 and 
𝑥 within each individual and thus not take into account the between-variation 
(Wooldridge, 2014). This is what we want, because differences between individuals 
are often not due to the treatment we are studying but are constant and present 
independent of treatment or not.  
In my analysis, patient fixed effects are used to control for fixed differences between 
patients over time. This means that we look at changes within each person, and thus 
exploit the within variation each person “creates” as the variables measured change 
over time. As patients do not change ward or NH in the study period, we thus also 
control for ward and NH fixed effects. To control for time-invariant differences are 
important because differences between patients can affect the dependent variable and 
lead to omitted variable bias. By using fixed effect regression, at least some of this 
bias is reduced, although one can never be sure that it is completely “taken care of”. 
In the fixed-effects regression, a critical assumption is that the unobserved 
heterogeneity is constant over time. In the context of the COSMOS study, the 
unobserved heterogeneity, such as chronic diseases or budget, are likely constant 
during the study period as our observation period is only 9 months. Even so, we 
cannot be sure that there has not been a change in for example chronic diseases 
during this period. If the unobserved heterogeneity is constant over time, the 
observed effect is more likely due to the intervention. 
5.4.3 Average treatment effect on the treated 
Since the effect of the intervention may be found by comparing the intervention and 
control group, I rely on a method that is methodologically very similar to a 
difference-in-difference (DiD) approach. It can formally be written as 
𝑦𝑖𝑡 = 𝛼 + 𝛽1𝑇𝑅𝐸𝐴𝑇𝑖 + 𝛽2𝑃𝑂𝑆𝑇𝑡 + 𝛼𝐴𝑇𝐸𝑇(𝑇𝑅𝐸𝐴𝑇𝑖 × 𝑃𝑂𝑆𝑇𝑡) + 𝜀𝑖𝑡   [4] 
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The dummy for treatment group is denoted 𝑇𝑅𝐸𝐴𝑇𝑖. Since no patient changes 
treatment status during the intervention period, this variable is constant over time 
and will be omitted because of the fixed effect regression. The dummy for post-
treatment period, 𝑃𝑂𝑆𝑇𝑡, varies over time and controls for the fact that, whether 
treated or not, conditions change. The interaction term 𝑇𝑅𝐸𝐴𝑇𝑖 × 𝑃𝑂𝑆𝑇𝑡 is the ATET 
(Angrist and Pischke, 2015). Mathematically it can be expressed by 
𝛼𝐴𝑇𝐸𝑇 = (?̅?𝑖𝑛𝑡𝑒𝑟𝑣𝑒𝑛𝑡𝑖𝑜𝑛,𝑝𝑜𝑠𝑡 − ?̅?𝑐𝑜𝑛𝑡𝑟𝑜𝑙,𝑝𝑜𝑠𝑡) − (?̅?𝑖𝑛𝑡𝑒𝑟𝑣𝑒𝑛𝑡𝑖𝑜𝑛,𝑝𝑟𝑒 −  ?̅?𝑐𝑜𝑛𝑡𝑟𝑜𝑙,𝑝𝑟𝑒) 
Though the method is the same, a DiD approach and causality interpretation will not 
be correct or reliable for this data set. This is because I cannot verify the identifying 
assumption for DiD; the common trends assumption, which tells us that in the 
absence of treatment, the two group-outcomes would move in parallel (Angrist and 
Pischke, 2015). Thus, prior to the introduction of a treatment the control and 
intervention group should follow a common trend in the variable inspected. To rely 
on DiD estimates, data on the outcome variables would have to be collected for 
multiple points in time before COSMOS was introduced for both groups. If they did 
not follow a common trend, we would not know if possible changes after treatment 
would be due to treatment, or something else that happened before treatment was 
introduced. For instance, if the intervention group was steadily upwards-trending in 
all time-periods before treatment, while the control group had a flat trend, some of 
the difference seen after treatment would most likely also have been observed without 
treatment. Consequently, a DiD approach has not been used, even though the 
methodology is the same. I will look at ATET over time, comparing the control and 
intervention groups in the post-treatment period. Even though I do not have 
information about the pre-treatment trends, patients are randomized to control and 
intervention groups. As mentioned, if randomization was successful, we can expect 
the two groups to be similar before treatment. Then observable differences after 
treatment should be the ATET due to the intervention. The balance checks show 
that only a few of the variables are statistically significant and the groups seem quite 
similar. This makes a successful randomization more believable and it is more likely 
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that the ATET is causal, especially after also controlling for fixed effects. Still, we 
have to remember the challenges discussed earlier. 
5.4.4 Standard error adjustment 
Clustered standard errors 
In panel data, the standard errors can suffer from serial-correlation and intraclass 
correlation. The problems arise when following individuals over time, and if groups of 
people within the sample are similar to each other. As pointed out by Moulton 
(1990), non-clustering the standard errors on these groups can lead to a down-wards 
bias in the OLS standard errors, which should be dealt with and adjusted for. 
Serial correlation is the tendency for one observation to be correlated with the 
observations in the periods before (Angrist and Pischke, 2009). If you observe a 
patient with depression and anxiety, it is more likely that you will also observe 
depression and anxiety in this patient in the next observation period. According to 
Angrist and Pischke (2009), the easiest and mostly used approach to this problem is 
to cluster on a higher level. In my case this means to scale up the clustering level 
from patient to NH wards, and from NH wards to NHs. The authors go on by saying 
that the reduced number of clusters is problematic. They claim that fewer than 42 
clusters could be worrisome, though this number is very uncertain. In my sample, the 
number of clusters are reduced from 66 to 31 when changing cluster levels from NH 
wards to NHs. This is a significant decrease, which can lead to problems such as 
biased standard errors and misleading inferences (Angrist and Pischke, 2009). In 
statistics, it is generally preferred to cluster on the highest level possible where we 
believe there is in-group correlation. For this reason, I have chosen to cluster on NH 
level. To correct for bias in the standard errors due to too few clusters, I have used 
bootstrapped standard errors, described below. 
In my study, patients from different NH are compared to each other. Observations 
within NHs are likely to be correlated with each other, and the standard errors 
should be adjusted to correct for this. The appropriate formula to use for this 
intraclass correlation is, again, the clustered standard errors, which allows for 
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correlated data within clusters defined by the researcher (Angrist and Pischke, 2009). 
This is sensible since we can assume that patients living in the same NH are more 
similar compared to patients living in other NHs, because they have equal conditions 
regarding NH economy, and socio-economic and geographical environment. Also, staff 
often interact or are involved in all or multiple wards in a NH. 
Bootstrapped standard errors 
The number of clusters needed to get unbiased standard errors is disputed, but my 
number of 31 is questionable. For this reason, a bootstrapping procedure can be used 
to obtain more accurate cluster-robust inference. Angrist and Pischke (2009) explains 
that Stata’s “cluster” option relies on the asymptotic approximation of many clusters 
or time series observations. As the number of clusters are not asymptotically large, 
bootstrapped standard errors can be a better approximation to unbiased standard 
errors. Based on asymptotic formulas, bootstrapping is a resampling scheme and 
offers an alternative to inference. A bootstrap sample is a sample randomly drawn 
from our own data. We treat our sample 𝑁 as the population and draw repeatedly 
from it, with replacement, and thus construct a sampling distribution for the “true” 
population 𝑁. When we treat 𝑁 as the population, we know the “true” errors and can 
approximate the standard error of the true distribution with the errors of the 
resampled data. The bootstrapped standard error is the standard deviation of the 
resampled data (Angrist and Pischke, 2009).  
More specifically, I have used block bootstrapping. Angrist and Pischke (2009) says 
that to preserve the clustered data’s dependence structure, the block bootstrapping 
method can be used. This means to resample the data by randomly drawing blocks of 
data defined by the cluster group. In my data, it is not individuals that are 
resampled, but NHs. The ideal number of repetitions is disputed, but the main 
concern is to run enough repetitions for the asymptotic properties to be realized. I 





The model used in the analysis is presented below. I estimate a fixed effects 
regression trying to identify the ATET of the COSMOS-intervention from baseline to 
the 9-month follow-up. This can be formalized in the following way: 
?̃?𝑖𝑡 = 𝛽𝑖𝑡𝑇𝑅𝐸𝐴𝑇𝑖 + ?̃?𝑃𝑂𝑆𝑇𝑡 + ?̃?𝐴𝑇𝐸𝑇(𝑇𝑅𝐸𝐴𝑇𝑖 × 𝑃𝑂𝑆𝑇𝑡) + 𝑐𝑜𝑛𝑡𝑟𝑜𝑙𝑠 + ?̃?𝑖𝑡 ,      𝑡 = 1,2,3  [5]      
                                                                               𝑖 = 1, … ,275                                   
The dependent variable ?̃?𝑖𝑡 is QoL, number of psychotropic medication, and formal- 
and informal time use. Cognition score was the only time-variant control variable 
that could not be suspected to be an outcome of the intervention and were therefore 
the only control variable included in the full model.  
Additionally, I look at the different components of formal and informal care 
separately. A sub analysis on the change in the care components ADL, IADL and 
supervision has been performed to better understand how the amount of formal- and 
informal care has changed. This can enlighten where the COSMOS-intervention has 
had the greatest effect. For instance, since ADL and IADL is where people with 
dementia are most dependent, an effectivization of ADL and IADL can be more 
important than that of supervision. Further, since the intervention was implemented 
between baseline and the 4-month follow-up, we can expect a larger effect between 
these points in time, than between 4- and 9-month follow-up. Therefore, separate 
interaction terms for 4- and 9-month are included. 
6. Results 
In this chapter the results from the analyses are presented. Each outcome gets a 
visual introduction, before the fixed-effects regression results are presented. For the 
first two outcomes, four estimation strategies leading to the full model are presented 
for the sake of comparisons. Issues that challenge the causality are described, and 






Figure 2 Change in QoL 
When visually inspecting the change in QoL in the two groups (Figure 2), it is 
apparent that the QoL-score only has a marginal change from baseline to month 9. In 
the second follow-up, the average QoL score slightly increases (QoL slightly worse) 
compared to baseline. Nevertheless, over time the QoL-score has been almost 
constant in both groups, and there are no apparent differences on average. 
Figure 2 can only tell us the descriptive association since it only displays the change 
in raw data. In Table 4, the estimation strategies attempting to find the causal effect 
of treatment are presented. To visualize how controls and fixed effects affect my 
results, different estimation strategies of how COSMOS has affected the patient’s 
QoL is presented. The estimation strategy in column (4) represents the full model 
and is preferred because fixed effects controls for time-invariant unobserved 
heterogeneity and including the time-variant control variable ‘development in 
dementia’ controls for a possible endogenous variable affecting our outcomes. 
Table 4 ATET of COSMOS on QoL 





























     








     








     








     

















Observations 822 411 822 822 
Controls No Yes Yes Yes 
FE No No Yes Yes 
* p < 0.10, ** p < 0.05, *** p < 0.01 
Note: Cluster bootstrapped standard errors in parentheses.  
This table presents various model specifications of mean difference over time on QoL. The first three columns 
include an interaction term where we look at the post-treatment period as one period, while in column (4) we look 
at each post-treatment period separately. Column (1) shows the results with no control variables or fixed effects. 
In column (2), time-invariant and time-variant control variables are included, and in column (3) and (4) time-
variant control variables and fixed effects are included. Time-invariant control variables include baseline 
measurement of pain, depression, agitation, ADL and neuropsychiatric symptoms score, marital status, age and 
sex. The time-variant control is change of cognition score over time. Standard errors are bootstrapped and 
clustered on NH level. 
 
When testing for differences in the intervention and control groups, no significant 
change in ATET on QoL can be seen from baseline to the 9-month follow-up; not 
with either estimation strategy. Including control variables and fixed effects do not 
increase precision. Since measuring QoL in people with dementia can be problematic 
in several ways, I have done a separate analysis on depression score, which can 
represent an objective measure of a person’s QoL. This association has also been 
found in the literature (Barca et al., 2011). The QoL-score and depression score were 
strongly correlated (0.6417). I also considered pain score, but the correlation between 
QoL and pain score was poor (0.2913). The regression results of ATET of depression 
score also shows non-significant results and can be found in the Appendix 3. This 
supports that there has been no a change in the measured QoL of the patients after 
the intervention.  
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6.2 Formal care 
 
Figure 3 Change in formal care 
In Figure 3, the development in formal care and the different components of formal 
care can be seen. a) displays the formal care in total, while b)-d) divides the total 
time use into the different components. A general tendency is that time use in the 
intervention group is increasing from baseline to the 9-month follow-up, while it in 
the control group is more constant. a) shows that the change in use of formal care in 
the intervention group is drastic; from baseline to the second follow-up, the mean 
increases from around 49 to 88 hours per month. The control group also has an 
increase in mean formal care, although much smaller, going from around 53 to 64 
hours per month. As suspected, general care is the component taking most of the 
formal caregivers’ time. In d) it is evident that supervision is affected the least in 
change over time and takes the least of the formal caregivers’ time. In the 
intervention group, formal care used on IADL has increased a great deal, as is 




Table 5 ATET of COSMOS on hours of formal care per month 
























     








     








     








     

















Observations 822 411 822 822 
Controls No Yes Yes Yes 
FE No No Yes Yes 
* p < 0.10, ** p < 0.05, *** p < 0.01 
Clustered bootstrapped standard errors in parentheses.  
Note: This table presents various model specifications of the ATET on formal care. The first three columns 
include an interaction term where we look at the post-treatment period as one period, while in column (4) 
we look at each post-treatment period separately. Column (1) shows the results with no control variables or 
fixed effects. In column (2), time-invariant and time-variant control variables are included, and in column 
(3) and (4) time-variant control variables and fixed effects are included. Time-invariant control variables 
include baseline measurement of pain, depression, agitation, ADL and neuropsychiatric symptoms score, 
marital status, age and sex. The time-variant control is change of cognition score over time. Standard errors 
are bootstrapped and clustered on NH level. 
 
In Table 5, the ATET on formal care is presented. After including control variables, 
the number of observations drop substantially, due to missing data. The interaction 
terms are significant on either a 0.10 or 0.05 level using the different estimation 
strategies, expect for the 4-month interaction in column (4). The full model shown in 
column (3) tells us that formal care per month has on average increased by over 20 
hours per patient in the intervention group compared to the control group. This 
translates into a 43 % increase in time use. In column (4), it is evident that only in 
the 9-month follow-up a significant change is found, with an increase in time use 
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equivalent to 53 %. All the following regressions include fixed effects and time-variant 
control variables. 
Table 6 ATET of COSMOS on components of formal care 
 (1) (2) (3) (4) (5) (6) 


































































       












       

























Observations 822 822 822 822 822 822 
* p < 0.10, ** p < 0.05, *** p < 0.01 
Clustered bootstrapped standard errors in parentheses.  
Note: This table presents the ATET on the three components of formal care. Columns (1), (3), and (5) include an 
interaction term where we look at the post-treatment periods as one period, while in columns (2), (4), and (6) we 
look at each post-treatment period separately. Control variables include change of cognition score over time. 
Standard errors are bootstrapped and clustered on NH level. 
 
The analysis of formal care components shows some interesting results and can be 
seen in Table 6. In line with the literature, the patients are most dependent in care-
tasks related to ADL, or general care, with about four times as much time use 
compared to IADL and supervision. The results indicate that there is an increase of 
around 11 and 7,5 hours per month in formal care used on ADL-related and IADL-
related tasks, respectively, in the intervention group compared to the control group. 
The results further suggest that there has been a change in IADL-tasks throughout 
the intervention, while in ADL-related tasks, only after the 4-month follow-up. There 
is no evidence of a significant change in time devoted to supervision. This suggests 
that changes in formal care is mostly driven by changes in IADL and ADL. Due to 
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higher precision, we can be more certain about the effect on COSMOS on changes in 
IADL, than ADL.  
6.3 Informal care 
 
Figure 4 Change in informal care 
Looking at Figure 4, it is apparent that informal care has changed over time. In a), 
we can see that the intervention group has a steady downwards sloping trend after 
the COSMOS-intervention. On the other hand, the control group has a mean increase 
of around 1 hour per month from before the intervention at baseline to the second 
follow-up. In b) and c) we can see that the amount of general care and everyday 
tasks performed in the intervention group has a downwards sloping trend, and has on 
average decreased by about 0.75 hours and 1 hour per month per patient, 
respectively. The development of time spent on supervision, which can be seen in d), 
is almost constant from baseline to 9-month follow-up, with a slight decrease in 
month 4. For the control group, informal care spent on everyday tasks, are constant 
over time. On the other hand, for general care and supervision, time used on informal 
care has increased somewhat on average. It is important to notice that hours of 
informal care have different pre-treatment levels in the two groups. In order to 
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identify a causal effect in this case, the estimation strategy used might not be 
sufficient. Additionally, information about pre-treatment trends are needed: We do 
not know if hours of informal care in the intervention group was already on a down-
wards sloping trend before treatment, and the opposite for the control group. Thus, 
the causality of the ATET should be interpreted with caution. 
Table 7 ATET of COSMOS on components of informal care 














































        














        














        














        





























Observations 822 822 822 822 822 822 822 
 
* p < 0.10, ** p < 0.05, *** p < 0.01 
Clustered and bootstrapped standard errors in parentheses.  
Note: This table presents the ATET on informal care and components of informal care. Columns (1), (3), (5), and 
(6) include an interaction term where we look at the post-treatment periods as one period, while in columns (2), 
(4) and (7) we look at each post-treatment period separately. Control variables include change of cognition score 
over time. Standard errors are bootstrapped and clustered on NH level. 
 
The regression of ATET in Table 7 shows that there with high precision is a decrease 
in hours of informal care of over 3 hours per patient per month on average in the 
intervention group compared to the control group. This amounts to an 80 % decrease 
from baseline levels. There is a significant change in the amount of informal care 
spent on general care and supervision: After the intervention, family and friends use 
about 1.5 hours less on help with general care-activities such as toileting, feeding and 
bathing, and around 1 hour less on supervision per patient per month. As for formal 
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care, informal care tasks related to ADL do not have a significant change before after 
the 4-month follow-up. For supervision on the other hand, the only significant finding 
is in month 4. More than 1,5 hours less informal care per month has been spent on 
ADL in month 9 and supervision in month 4. No significant change is seen in IADL-
related tasks. The coefficient “after” shows that the control group has a significant 
increase of informal care going from baseline to post-intervention, expect for in tasks 
related to IADL.  
6.4 Psychotropic medication 
 
Figure 5 Change in psychotropic medication 
The first impression of change in psychotropic medication when examining Figure 5, 
is that use of medication decreases slightly in the intervention group, while staying 
relatively constant in the control group. The biggest impact in the intervention group 
happens from baseline to the first follow-up around month 4, while it from then to 
the 9-month follow-up almost does not change at all.  
Also here the pre-treatment levels are different, although not to a great extent. Even 
so, information of pre-treatment trends would be useful, and the causal effect must be 
interpreted with caution. The ATET of COSMOS on use of psychotropic medication 
can be seen in Table 8. The results showed a statistical significant decrease in use of 
psychotropic medication from baseline to month 4 in the intervention group 
compared to the control group. This indicates that the intervention has decreased the 
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use of psychotropic medication in the first follow-up month, but not further after 
month 4. The average use in the intervention group in month 4 decreased by 0.126, 
giving a decrease in use of psychotropic medication of over 10 % from baseline to 4-
month follow-up.  
Table 8 ATET of COSMOS on use of psychotropic medication 










   




   




   




   









Observations 822 822 
* p < 0.10, ** p < 0.05, *** p < 0.01 
Clustered bootstrapped standard errors in parentheses.  
Note: This table presents the ATET on use of psychotropic drugs. Column (1) include an 
interaction term where we look at the post-treatment periods as one period, while in 
column (2) we look at each post-treatment period separately. Control variables include 
change of cognition score over time. Standard errors are bootstrapped and clustered on NH 
level. 
 
6.4 Possible challenges and robustness tests 
6.4.1 Possible challenges 
It is challenging to control for everything that can affect the results, and there is 
probably omitted variable bias (OVB) in this model. Although the fixed effects 
regression controls for time-invariant omitted variables, like discussed in section 5.4.2, 
there may still be time-variant variables that are not controlled for. If the time-
variant omitted variables affect the intervention and control group differently, the 
causal effect of the intervention is biased. One example is how the general health 
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changed after the intervention period, where information was available, though only 
after the intervention. It turns out that the patients in the control group had a higher 
health deterioration than the patients in the intervention group during the 
intervention period. If the patient had a worsening or improvement in their health, 
this could affect their QoL or time use regardless of the intervention. When health is 
declining, the patient becomes frailer, needs more medication, or more supervision, 
and we can expect the patient to become more dependent on his or her caregivers. 
Therefore, it is a possible that some of the difference observed between the groups, is 
in fact due to differences in general health. Since the patients in the control group 
had a bigger health deterioration, the QoL-estimation can be down-wards biased and 
the formal care-estimation can be upwards-biased in the control group, and then also 
the causal effect of the intervention can be biased. There are various other control 
variables that would have been beneficial to have, reducing the possibility of OVB. 
For instance, the presence of chronic diseases and other comorbidities would be useful 
to control for. A change of these factors may have affected formal time use, for 
instance if the patients become bedridden. Also, access to staffing can affect available 
formal care if someone gets long-term illness, or if someone quit. 
Another issue is the small sample size. A bigger sample could show different results – 
for both the coefficient and the significance level. The LLN works when 𝑛 → ∞ , and 
my sample may be too small for its properties to properly kick in. As mentioned in 
section 5.2.1, a problem can be that if the sample size increase, differences observed 
at baseline can diverge and become statistically significant. 
As mentioned by the COSMOS-researchers themselves, we expect the control group 
to also have an effect of the intervention. If this is the case, the effect of the 
intervention is underestimated and could also be the reason for not finding a 
significant difference between the two groups in some of the outcome variables.  
6.4.2 Robustness tests 
When including patients in the sample, I performed a listwise deletion of patients 
with missing values in the variables determining cognitive level at baseline and QoL. 
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When a listwise deletion is performed, all patients with a missing value in the 
relevant variable are excluded. This was, as mentioned before, because the inclusion 
criteria could have been violated if these individuals were included. Even so, this can 
still be problematic as important variation may have been deleted. Also, patients 
with missing values in the dependent variables were excluded. In total, 206 patients 
were excluded, which is a considerable amount, and a lot of variation was lost due to 
this. As a robustness test, I wanted to inspect if there was a systematic difference in 
the excluded and included patients. In Appendix 4, the descriptive statistics from 
baseline of the excluded patients can be seen. In general, they were relatively similar 
to the patients included in the sample. On average, they were a little older and more 
demented. They also used a little more formal care and a little less informal care. 
Many of these patients died during the study period, and it thus makes sense that the 
excluded patients are older, more demented and contributed a higher care-burden. It 
is common that patients of older age, have more advanced dementia and 
demonstrates a higher care-burden towards the end of life. Including the 206 excluded 
patients, I also performed the fixed effect regressions to investigate how the excluded 
patients affect the results. The results can be found in Appendix 4. Compared to the 
full model, the regressions show a significant decrease in QoL in the control group 
after the intervention, but there is still no difference between the groups. The change 
in formal care is almost identical, while there are some differences in the change in 
the components of formal care with generally smaller estimates. For informal care the 
results are also similar to the full model, with somewhat smaller estimates. For 
psychotropic medication the interaction term is now significant, and the estimated 
decrease in use of psychotropic drugs are higher. 
There can be problems regarding the level of clustering. I chose to cluster on NH level 
to control for correlation between patients residing in the same NH. This resulted in 
31 clusters. Another possibility was to cluster on ward level, which would give 66 
clusters. 31 clusters can be too few, and as a result the standard errors were 
bootstrapped. A possibility is that clustering on NH wards would have been a 
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sufficiently “high” level where there is suspected correlation, and that this would be a 
better choice. To check whether choice of clustering level and bootstrapped standard 
errors affected my estimates to a high degree, I compared the estimates when the 
different model specifications were applied. They can be found in Appendix 5 and 
show that the standard errors are relatively similar. Formal care is only significant 
when clustering at NH level, but is very close to becoming significant (p-value=0.108) 
when clustering on ward level. Changing clustering levels, both increased and 
decreased precision in some outcome variables in the different model specifications. 
Bootstrapping increased precision in one of the outcomes (informal care), but the 
standard errors did not change much. This can indicate that the non-bootstrapped 
standard error is a good approximation of the population. 
Since we are looking at the average treatment effect over time, a source of concern is 
that the results are driven by a few patients that have become more time-consuming 
due to something unrelated to the intervention, e.g. due to an infection, pressure 
ulcer or other diseases, or because they are towards the end of their lives. To 
approach this challenge, I excluded all patients that had a change of formal care use 
> 200, which resulted in the deletion of 10 patients. I ran the same fixed effects 
regressions, and the results can be found in Appendix 6. They show that there is no 
longer a significant change of formal care hours in the intervention group compared 
to the control group. This may indicate that the results are driven by a few 
demanding individuals, and that the final results can be biased. Due to this, 
quantifying the median change instead of the average could be preferred. However, all 
patients but one, were in the intervention group, and the increased time use might 
likely be a result of the intervention.  
Even though perfect randomization is difficult to achieve, the randomization seems 
quite successful. Thus, the fixed effect model may be redundant, and a model without 
fixed effects could have been more appropriate. Therefore, I checked how the results 
changed when not including fixed-effects, and with baseline control variables. The 
results, which can be found in Appendix 7, still show no significant change in QoL. 
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There is still a significant change in formal care and in the components general care 
and everyday tasks, though the coefficients are generally smaller. Also, informal care 
and the general care-component are significant, though also here the coefficients are 
generally smaller. No significant difference in supervision is found. Difference in 
psychotropic drug use is no longer statistically significant at month 4 (p-value=0.12). 
Without fixed effects, the results are still somewhat similar, and can indicate that 
time-invariant unobserved heterogeneity is present but not a big problem in this 
sample.  
6.4.3 Measurement errors 
There can be some challenges connected with the questionnaires used. One is if the 
sensitivity of the QoL-instrument is good enough. To get an impression of the 
sensitivity of the QoL-instrument, I inspected how the measured QoL changed for the 
patients that was admitted to a hospital during the intervention period. We would 
expect the negative side-effects due to the incidence leading to hospital admission, 
like falling, to be picked up by the QoL-instrument. But, visually inspecting the 
change in both groups show an almost constant development (Appendix 8).  
There are also some drawbacks concerning how formal time use is measured, which 
reduces the reliability of the findings of time use. If the time use is not recorded 
correctly, it will not be a representation of reality. In COSMOS there was no time 
schedule where all caregivers recorded their time spent on direct care after their shift 
was over, like suggested in a study by Luttenberger and Graessel (2010). A caregiver 
who worked day shift would fill in the form, with only information about the daytime 
direct care. This is a weakness on how the resource use data is collect, as the daytime 
health care personnel does not know how much time personnel on night or evening 
shift spent on direct care. On the other hand, most direct care time will take place 
during the day, as the majority will sleep during the night shift. But even so, the 
direct care time performed during the evenings and night will either not have been 
included in the total care time, or it has been estimated by someone who was not 
there. This can to some degree make the recording of care time incorrect. Another 
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drawback of the RUD-FOCA is that it does not take group activities into account. 
Thus, we do not know if some of the recorded time was used in group activities, and 
that we have some double-counting in the measurements. The drawbacks of how time 
use is measured can create measurement errors and bias the true formal- and 
informal time use. Another challenge is that this measurement error can be different 
in the control and intervention group, which would bias our causal effect of the 
intervention. However, we cannot know how much, if any, of the difference is due to 
these setbacks.  
7. Discussion 
The results show no significant change in QoL for people with dementia after 
COSMOS was introduced. Regarding the measures for resource use, formal care has 
increased drastically, while informal care and psychotropic medication has decreased, 
but to a lesser extent. This chapter discusses the results in view of the literature and 
tries to shed light on the economic implications of the intervention. The economic 
implications are discussed from the perspectives of the patient, the NH management 
and society. 
7.1 QoL 
Earlier, the challenges with measuring QoL in a population of people with dementia 
and the dispersed finding in research was discussed. QoL is a subjective construct, 
and thus difficult to measure truthfully in this population, because the disease 
prevents them from being able to communicate and comprehend their QoL, and one 
has to rely on proxy-rated QoL. Proxy-rating of QoL has been found to be both in 
compliance and non-compliance with self-reports, but are often underestimated 
(Robertson et al., 2017). If the patients were reliably able to fill out the 
questionnaires in the COSMOS-study themselves, the results may have been 
different. QoL can have been affected by the intervention, maybe on a level that is 
difficult to measure in a questionnaire like QUALID. When measuring QoL with 
53 
 
QUALID, QoL is transformed into an objective thing by measuring how often the 
patients smiles, cries, seems sad and so forth. But in reality, QoL incorporates much 
more than outward expressions and behaviors. Another potential issue is that the 
proxy-rated QoL is biased by the proxy-raters perception of the disease and the 
impact it has on a persons’ life (Moyle and Murfield, 2013). These challenges can also 
be present in the COSMOS-study and can be a reason for finding non-significant 
results. The subjective part of QoL is not measured in this study because it is not 
possible, but subjectively the patients may have experienced a changed QoL.  
7.2 Economic implications  
The society’s resources should be used efficiently. Resources spent on COSMOS 
should be the best possible utilization, and the opportunity cost of the resources 
should be low. Ergo, the value foregone by not using the resources on the best 
possible alternative to COSMOS ought to be low. In any efficiency analysis, like a 
cost-benefit analysis (CBA) or a cost-utility analysis (CUA), one must always weigh 
the costs up against the benefits. What is viewed as the optimal utilization of the 
resources will be contingent on whether you ask the patients themselves, the NH 
management, or the Government, because they value costs and benefits differently. 
When taking the societal perspective, the society’s welfare as a whole must be taken 
into account. When taking the patient’s or NH’s perspective, the welfare of society in 
total is not considered, rather the relevant costs and benefits for either the patient 
himself or the NH. According to the Norwegian Directorate for Health’s guidelines for 
economic evaluation in the health sector, it is recommended for analyses in the health 
care sector to be conducted in a societal perspective (The Norwegian Directorate of 
Health, 2012b). A key question in any decision-making process is what the 
intervention is compared to. The most common reference case is “care as usual” (The 
Norwegian Directorate of Health, 2012b). Compared to “care as usual”, implementing 
the COSMOS-intervention increases formal care, decreases informal care and use of 
psychotropic medication, and has no effect on QoL, if the results are interpreted as 
causal. If the intervention is beneficial, the sum of benefits exceeds the sum of costs. 
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Since the various effects of the intervention are not valued, it is difficult to know 
whether the sum of benefits exceeds the sum of costs. To do a proper CBA or CUA, 
all factors should be taken into account and valued. Since this is outside the scope of 
this text, I will discuss the observed benefits and costs related to the intervention, 
and what consequences it can lead to from the various perspectives; societal, patient 
and NH management. In table 9, an overview of what is considered benefits and costs 
in the various perspectives in my discussion can be seen. 
Table 9 Costs and benefits in different perspectives 
Increase in 
 
 Perspective  
Societal NH Patient 
Formal care time cost/benefit cost/benefit benefit 
Informal care time cost/benefit benefit benefit 
Psychotropic medication cost cost cost 
QoL benefit benefit benefit 
    
 
7.2.1 Formal care 
The amount of formal care has increased tremendously. An increase of approximately 
20 hours of formal care per patient per month is equivalent to around 45 minutes per 
patient per day, on average. For this to be possible without hiring extra staff in the 
intervention period, it seems unlikely that the staff have used their time very 
efficiently before the intervention. Alternatively, they must have spent less time on 
administrative tasks, talking with colleagues, or other activities that are not 
measured, and more time on the patient, after the intervention. There is no 
information about the change in staffing, but as the NHs received no extra resources 
in connection with the intervention, it is likely that the staffing stayed constant. On 
the other hand, they can have hired more staff7 to be able to successfully carry out 
                                      
7 Due to the interventions short time-span, calling part-time workers in for more extra shifts than 
usual is the most likely scenario 
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the intervention. This would be important to have information on, as costs would 
then be largely affected. If the staff was very inefficient before the intervention (for 
instance used much of their time on non-caring activities), it caused efficiency gains if 
no extra staffing was required. Then the increased time use can be viewed as a 
benefit in both the NH management and societal perspective. This possible gain is 
not reflected in the development in QoL, however. On the other hand, if more staff 
would have to be hired, this would lead to increased costs. Another possible cost is if 
the staff already was efficient before the intervention. Then it can be argued that if 
the same staff use much more time, they spend their time more inefficiently. For the 
patient, increased time use is most likely a pure benefit, if he gets increased attention 
and more thorough care. A setback is that we do not actually know if the staff has 
increased their efficiency or not after the intervention, as this is not measured.  
7.2.2 Informal care 
After the COSMOS-intervention the amount of informal care has decreased with over 
3 hours per patient per month. Since Vossius et al. (2015) found that informal care in 
Norwegian NHs amounts to 6.7 hours per month on average, a decrease of over 3 
hours is a considerable amount. A reason for the need for informal care, can be due to 
understaffing. Informal caregiving measured with the RUD-FOCA questionnaire can 
be a sign of the formal caregivers not doing their job properly – at least in the eyes of 
family members or friends. For instance, if a patient needs to use the restroom while 
a family member is visiting, the next of kin might feel obliged to perform the task if 
the personnel is not immediately available. Understaffing can be reflected in the 
personnel per patient ratio. At baseline, the ratio during daytime is on average 0.34 
in the NHs. In the evenings the ratio drops to 0.24. In Norway there is no mandated 
personnel-patient ratio, and one cannot say that this is too low according to a 
national standard. But it is plausible that the ratio is low enough for the patients 
having to wait for care, so that the informal caregivers feel the need to step in – 
especially in the evenings. In Norway, NHs are funded by the municipalities. To a 
large extent, each municipality’s economy and political prioritizations will thus decide 
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the level of care and staffing. The amount of staffing varies greatly across the 
municipalities, unrelated to patient care-burden (Dokument 8:155 S (2010–2011), 
2011). From a societal and NH management perspective, fewer informal care hours 
can lead to increased costs. This is especially true for municipalities with lower 
resource allocation to NHs. If the informal caregivers stop doing the care-tasks, 
someone else will have to fill the “void”. Informal care can be a huge resource to 
society, and with the increasing demand of health care due to the aging population it 
will likely become more and more important, as future projections show a shortage of 
health care personnel (The Norwegian Directorate of Health, 2012a). If the resources 
available are too scarce to properly fill the care-need (e.g. understaffing), the unpaid 
informal carers could cover care-needs otherwise not fulfilled. Therefore, a decrease in 
informal care can lead to higher costs for the society and NH management.  
When an informal caregiver spends his or her time doing care chores, it is at the 
expense of something else. There is an opportunity cost when performing informal 
care, which can incur a cost in a societal perspective. The caregiver could be spending 
quality time with the patient, working, using their free-time doing leisure activities or 
voluntary work, or just relaxing after a though week at work. Instead he or she can 
feel obliged to spend their time caring for a relative, maybe due to a sense of 
commitment or bad conscience. The literature shows that also in the NH setting, 
informal care can be stressful and be experienced as a burden for the informal carer 
(Gautun and Bratt, 2017). Health decline and stress can be a source of opportunity 
costs, as the care-tasks can be exhausting and, especially for the elderly caregivers, 
“steal” time that could otherwise be spent on, for instance, needed rest. Thus, a 
decrease of informal care can also be a benefit in a societal perspective. There is not 
much information on who the informal caregivers are, or why they participate in care 
tasks even after a relative or friend is admitted to a NH. Most of them are probably 
wives or husbands, adult children and friends. Many do most likely have a job, while 
some are retired. In fact, the descriptive statistics shows that only about 25 % of the 
patients were married, and we can thus expect many of the informal caregivers to be 
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adult children caring for their parents, and many of them having a job. There are 
different ways to value informal care, and one widely used method in economic 
evaluations is the opportunity cost method (Berg et al., 2004). For the working 
caregivers, the hours spent on informal care can be valued as their hourly salary. For 
retired spouses, the opportunity cost of informal care can be linked to foregone leisure 
time to spend with friends and family, needed rest or time to perform house chores. 
Normally one would value leisure time according to the hourly wage, but retirees do 
not have a job. A more appropriate valuation to the opportunity cost of wage can in 
this case be the replacement cost approach. This approach uses the market price of 
an equivalent service; in other words the price of a formal caregiver (Escribano-Sotos 
and Pardo-García, 2015). This can be a better valuation approach because the 
informal carer are doing work that a formal carer should be doing.  
7.2.3 Psychotropic medication 
There are two possible channels of efficiency in the reduction of psychotropic 
medication – reduced direct costs and less negative side-effects. The use of 
psychotropic drugs has decreased with over 10 % compared to the baseline levels and 
represents reduced direct medical costs for the society and NH. As the literature 
describes, psychotropic medication is related to negative side-effects. This can be 
regarded as intangible costs and are costs accounted for in the patient and societal 
perspective. As the there is no proof of change in the QoL-measurement, the 
intangible costs seem to be unchanged.  
Superfluous psychotropic medication has also been related to increased hospital 
admissions (Johnell et al., 2017), because overuse of medications can lead to serious 
side-effects and mistreatment. A decrease in psychotropic medication can thus be 
cost-saving in a societal perspective. Performing medication reviews were a part of 
the COSMOS-intervention, and my results indicate that the medication reviews have 
successfully reduced the use of psychotropic medication. In the White Paper on 
Medical Products – Correct use - better health the Norwegian Ministry of Health and 
Care Services suggests that a medication review for NH patients should be 
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mandatory. Their motivation is that a medication review will increase the quality of 
care and the safety of the patient, lead to better health, and can result in fewer 
hospital admissions (Meld. St. 28 (2014–2015), 2015). When checking how 
hospitalization has changed during the intervention period, I found no increase in 
hospitalization in the control group, while ten more patients are hospitalized going 
from month 4 to month 9 in the intervention group. The descriptive statistics can be 
found in Appendix 9. This indicates that reduced use of psychotropic medication does 
not lead to fewer hospital admissions in the short run. Since we do not have data on 
the patients’ hospital use before the intervention, we do not know the change before 
and after, and thus not the causal relationship between hospital use and the 
COSMOS-intervention. But this finding can indicate that COSMOS has increased 
hospital admissions. 
7.2.4 Psychotropic drugs or time use 
The literature shows some evidence which points to that use of psychotropic 
medication depends on the use of formal care, and that they may work as substitutes 
(Cawley et al., 2006, Schmidt et al., 1998, Anderson et al., 2016). To claim that these 
resources are substitutes on the background of my data and results can be going too 
far, as the divergency could be unrelated to each other. Even so, my results can 
indicate that there is an association between them, though a causal relationship 
cannot be stated. If there is shortage of staff, psychotropic medication can be a mean 
to fill this shortage. My findings show a negative correlation between formal care and 
psychotropic medication. This can point to that when formal care goes up, the care-
needs are filled to a larger degree by the caregivers and that the use of psychotropic 
medication then goes down. To the best of my knowledge, the estimated elasticity of 
substitution in this setting is not known. Thus, we don’t know how big of a change 
one would expect in psychotropic medication if formal care change, or vice versa. 
As labor is much more expensive, changing to more material-intensive methods can 
be a way of saving resources for society and the NH management. Using psychotropic 
medication as a substitute for labor, at least to a certain degree, can be especially 
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useful due to future projections of under-staffing in the health care sector and the 
growing number of elderly. It can be critical to rely on medication to some degree; 
not to make the patient dopey, but to avoid very burdensome behaviors, like 
aggression or agitation. My findings show that decreased medication and a 
substantial increase of labor does not affect the patients’ QoL, neither in the proxy-
rated or objective measure. If QoL is not negatively affected, using material-intensive 
methods up to a certain degree can be economically efficient. 
The literature also shows that more use of psychotropic medication is related to less 
staff, especially less educated staff, and staff distress (Anderson et al., 2016). 
Educated personnel will to a higher degree know how to handle, for instance, agitated 
patients and handle a stressing situation more efficiently because they know exactly 
what to do. Even though we know that the number of personnel and educated 
personnel were similar in the two groups at baseline, educated personnel in one group 
can by chance have been reduced, due to for instance absence. Having information 
about the change in staffing and of potential differences between the intervention and 
control group, could give a better understanding of psychotropic medication 
potentially working as a substitute for either (the lack of) staff in general or educated 
staff in specific. 
7.3 Time horizon 
The time horizon can affect the cost-effectiveness between the intervention and the 
reference case (care as usual), and should therefore be long enough for costs and 
health effects between the alternatives to be identified (The Norwegian Directorate of 
Health, 2012b). In this case, we only know the short-term effects of the intervention. 
The long-term effects can be different, and all costs and health effects are thus not 
identified. Especially, the substitution of formal care and psychotropic medication can 
be thought about as a process that is ongoing for a longer period of time, maybe after 
longer periods with a lot of pressure on the staff due to understaffing or long-term 
sickness. The empirical evidence linking QoL and psychotropic medication is as 
discussed earlier not clear, though psychotropic drugs are associated with an 
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increased risk of for instance seizures and falling, which we can expect to have a 
negative impact on QoL. But, I have found that even though there has been a 
reduction of these drugs, QoL has not changed significantly. A reason for not finding 
a significant change, can be that the decrease of psychotropic drugs is not large 
enough for an effect to be visible on QoL on the short-term. Side-effects such as 
increased risk of seizures are factors typically identified on the long-term. Thus, an 
intervention stretching for nine months may have a timespan too short for capturing 
such effects and how they could affect QoL. 
Also, it would be interesting to know to what degree the knowledge obtained during 
the intervention has been internalized by the staff. When the intervention started, 
the health personnel might be very motivated, and feel more responsible as they got 
continuous follow-ups throughout the study period. After the intervention was over, 
they might lose motivation or feel less obliged to perform the changes introduced by 
the COSMOS-intervention and more or less go back to the routines they had before. 
Alternatively, they have internalized the new knowledge and will continue with what 
they have learned. Since the intervention was aiming at increasing knowledge and 
focusing on training staff, a longer time-span or yearly follow-up would be interesting 
and beneficial. If the intervention had a longer time-span, better statistical power 
could have been reached and the credibility of the results increased. A problem is 
that elderly people with dementia doesn’t have a long life-expectancy, and we could 
risk losing a large part of the sample towards the end of the study. 
8. Concluding remarks 
Considering the large costs of dementia, both direct and intangible, interventions that 
increase efficiency in dementia care is valuable. Also, since the dementia disease is 
non-reversible and still untreatable, assuring the highest possible QoL can be the 
most important mission in health care regarding elderly people with dementia. The 
COSMOS-intervention intended to improve both cost-effectiveness and QoL. This 
thesis shows that after the COSMOS-intervention, the patients with dementia had no 
61 
 
significant change in QoL, formal care increased substantially, and informal care and 
use of psychotropic medication decreased. A possible explanation for finding no 
significant effects on QoL, can be related to the challenges of measuring QoL in 
people with dementia.  
Whether the intervention seems economically desirable and improved cost-
effectiveness, depends on the chosen perspective. There are indications of the 
intervention making it possible for informal carers to perform fewer care-tasks. This 
can lead to an increase in both benefits and costs for society, but since they are 
unvalued we cannot know which one exceeds the other. Additionally, QoL is 
unaffected and there is no evidence of decrease in hospitalization, while use of formal 
care increased. Increased costs may thus exceed benefits in a societal perspective. 
From the NH managements perspective, except maybe if the increased formal time 
use is due to more efficient time use, the benefits do not seem to exceed the costs. In 
the perspective of the patient, there is no apparent increase in costs. The patient 
experiences lower long-term risks of negative side-effects due to decreased use of 
psychotropic drugs, gets more formal care hours and QoL seems to be unaffected by 
less time spent with informal caregivers. This indicates that the benefits outweigh the 
costs for the patient. There are some indications of psychotropic drugs and formal 
care depending on each other, though the correlation is not very strong. To a small 
degree, increased formal care may have led to reduced dependency on psychotropic 
drugs. The causality of the results should be interpreted with caution due to various 
factor, such as a small sample size and the fact that also the control group were 
expected to have a learning-effect. Since none of the outcomes are valued, 
determining whether the intervention is efficient or not is challenging. These 
reasonings do not take into consideration if and how the other outcomes of the 
COSMOS-intervention changed (for instance change in activities, other drugs etc.), 
which may lead to a different conclusion.  
Regardless of whether the intervention is efficient or not, it can still give us valuable 
information about the relationship between the outcomes investigated. It can also tell 
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us something about how the population of elderly people with dementia responds to 
changes in these areas. This information can be used when optimizing care and it can 
give us knowledge on how resources can be used efficiently in the future.  
8.1 Future research 
In the process of writing this thesis, several questions have emerged that would be 
interesting to pursue. Due to the limited scope of this text, I could not go further 
with these questions, but recognize that they can be of value for future research. 
Regarding the relationship between staffing, psychotropic medication and 
hospitalization, some questions arises: Does understaffing lead to more frequent use of 
psychotropic medication in Norwegian NHs? Can more staff lead to less costs in the 
long-run due to fewer hospitalizations and consequences of side-effects? Are 
psychotropic medication and formal care substitutes? These are questions that future 
research should pursue, as a part of securing efficient use of the resources in the 
future. 
It would be interesting to know to what degree informal- and formal care in a NH 
can be substituted. Will increased informal care lead to decreased formal care? If so, 
this can be an important resource to utilize in the future, due to future projections of 
shortage of health personnel. Future research should investigate the causal 
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Appendix 1 Access to various personnel: Descriptive Statistics at Baseline 
 Proportion of wards    
 Intervention Control Difference p-value t-value 
Physical therapist 0.48 0.50 -0.02 0.898 0.13 
      
Priest 0.66 0.69 -0.03 0.769 0.29 
      
Dentist 0.62 0.69 -0.07 0.577 0.56 
      
Hair dresser 0.90 0.81 0.09 0.351 -0.93 
      
Volunteers 0.59 0.65 -0.06 0.606 0.52 
      
Occupational 
therapist 
0.21 0.23 -0.02 0.831 0.21 
      
Social worker 0.00 0.15 -0.15 0.028* 2.17* 
      
Chiropodist 0.86 0.81 0.05 0.586 -0.54 
      
Activities 0.59 0.54 0.05 0.721 -0.36 
N 29 26    
* p<0.05, ** p<0.01, *** p<0.001 


















Appendix 3 ATET of COSMOS on depression 
ATET of COSMOS on depression   










   




   




   




   









Observations 632 632 
* p < 0.10, ** p < 0.05, *** p < 0.01 
Clustered standard errors in parentheses.  
Note: This table presents the mean difference over time for use of psychotropic drugs. Column (1) include an interaction term 
where we look at the post-treatment period as one period, while in column (2) we look at each post-treatment period separately. 




Appendix 4 Excluded patients: Descriptive statistics and regressions 
  Intervention  Control  Difference  
 Scale Mean se Mean se p-value t-value 
Demographics and Health        
        
Age year 86.59 (7.96) 88.16 (7.38) 0.148 1.45 
        
Men (proportion) share 0.31 (0.46) 0.28 (0.45) 0.664 -0.43 
        
Weight (kg) kg 64.92 (14.34) 61.21 (13.73) 0.074 -1.80 
        
Height (m) m 1.63 (0.09) 1.64 (0.08) 0.346 0.95 
        
Blod pressure  128.40 (21.17) 128.01 (23.54) 0.907 -0.12 
        
Blod pressure  70.69 (12.69) 71.36 (13.80) 0.734 0.34 
        
Pulse  73.59 (12.32) 71.00 (11.68) 0.152 -1.44 
        
Scores from COSMOS-study        
        
Formal care (RUD-FOCA) hrs/month 65.56 (51.76) 57.76 (51.94) 0.300 -1.04 
        
Informal care (RUD-FOCA) hrs/month 2.10 (5.91) 2.98 (10.01) 0.454 0.75 
        
QoL-score (QUALID) 11-55 20.86 (7.75) 21.65 (9.24) 0.509 0.66 
        
Cognitive status (MMSE) 0-30 8.25 (7.43) 7.38 (7.35) 0.395 -0.85 
        
Pain-score (MOBID) 0-10 2.27 (2.37) 2.92 (2.66) 0.094 1.68 
        
Agitation-score (CMAI) 29-203 41.58 (12.89) 42.70 (14.83) 0.578 0.56 
        
Activities-of-daily-living-score 0-30 23.62 (13.38) 20.50 (12.36) 0.085 -1.73 
        
Psychiatric-symptoms-score 0-120 15.00 (17.19) 16.20 (17.49) 0.636 0.47 
        
Caregiver-distress-score 0-50 7.50 (6.89) 6.39 (6.14) 0.271 -1.11 
        
Depression-score 0-38 6.14 (5.19) 7.88 (7.19) 0.094 1.69 
        
Psychotropic drug use        
        
Use of antipsychotics n 0.15 (0.39) 0.16 (0.39) 0.975 0.03 
        
Use of anxiolytics n 0.21 (0.43) 0.24 (0.43) 0.612 0.51 
        
Use of hypnotics and sedatives n 0.30 (0.50) 0.27 (0.45) 0.661 -0.44 
        
Use of antidepressants n 0.51 (0.67) 0.38 (0.57) 0.127 -1.53 
        
Use of anti-dementia drugs n 0.16 (0.37) 0.17 (0.37) 0.954 0.06 
        
Use of total psychotropic 
drugs 
n 1.34 (1.22) 1.21 (1.21) 0.452 -0.75 
        
N  110  96  206  
Notes: This table shows the t-statistics of mean differences at baseline in the intervention and control group for the patients that 
was excluded due to missing values. Standard deviations in parentheses. 





ATET of COSMOS on QoL 


















     








     








     








     

















Observations 1566 744 1566 1566 
* p < 0.10, ** p < 0.05, *** p < 0.01 
Note: Cluster bootstrapped standard errors in parentheses.  
This table presents various model specifications of ATET for formal care. The first three columns include an 
interaction term where we look at the post-treatment period as one period, while in column (4) we look at each 
post-treatment period separately. Column (1) shows the results with no control variables or fixed effects. In 
column (2), time-invariant and time-variant control variables are included, and in column (3) and (4) time-variant 
control variables and fixed effects are included. Time-invariant control variables include baseline measurement of 
pain, depression, agitation, ADL and neuropsychiatric symptoms score, marital status, age and sex. The time-




ATET of COSMOS on hours of formal care per month 



























     








     








     








     

















Observations 1302 624 1302 1302 
Controls No Yes Yes Yes 
FE     
* p < 0.10, ** p < 0.05, *** p < 0.01 
Clustered bootstrapped standard errors in parentheses.  
73 
 
Note: This table presents various model specifications of the ATET for formal care. The first three columns 
include an interaction term where we look at the post-treatment period as one period, while in column (4) 
we look at each post-treatment period separately. Column (1) shows the results with no control variables or 
fixed effects. In column (2), time-invariant and time-variant control variables are included, and in column 
(3) and (4) time-variant control variables and fixed effects are included. Time-invariant control variables 
include baseline measurement of pain, depression, agitation, ADL and neuropsychiatric symptoms score, 
marital status, age and sex. The time-variant control is change of cognition score over time. Standard errors 




ATET of COSMOS on categories of formal care 
 (1) (2) (3) (4) (5) (6) 
























































       












       

























Observations 1555 1555 1552 1552 1561 1561 
* p < 0.10, ** p < 0.05, *** p < 0.01 
Clustered bootstrapped standard errors in parentheses.  
Note: This table presents the ATET for three components of formal care. Columns (1), (3), and (5) include an 
interaction term where we look at the post-treatment periods as one period, while in columns (2), (4), and (6) we 
look at each post-treatment period separately. Control variables include change of cognition score over time. 




ATET of COSMOS on informal care  


























































































































Observations 1297 1297 1561 1561 1555 1564 1564 
* p < 0.10, ** p < 0.05, *** p < 0.01 
Clustered and bootstrapped standard errors in parentheses.  
Note: This table presents the ATET for informal care and components of informal care. Columns (1), (3), (5), and 
(6) include an interaction term where we look at the post-treatment periods as one period, while in columns (2), 
(4) and (7) we look at each post-treatment period separately. Control variables include change of cognition score 




ATET of COSMOS on use of psychotropic medication 










   




   




   




   









Observations 1336 1336 
* p < 0.10, ** p < 0.05, *** p < 0.01 
Clustered bootstrapped standard errors in parentheses.  
Note: This table presents the ATET for use of psychotropic drugs. Column (1) include an 
interaction term where we look at the post-treatment periods as one period, while in 
column (2) we look at each post-treatment period separately. Control variables include 











Appendix 5 How precision is affected: Clustering and bootstrapping 
 
 (1) (2) (3) 
 Cluster: ward Cluster: NH Cluster: NH & bootstrapped 































    
Psychotropic medication    






    
Observations 822 822 822 
* p < 0.10, ** p < 0.05, *** p < 0.01 
Note: This table shows how the precision of estimates of the dependent variables change, depending on cluster 





Appendix 6 Exclusion of patients with large change in formal care 
 
ATET of COSMOS on hours of formal care per month 



























     








     








     








     

















Observations 792 399 792 792 
Controls No Yes Yes Yes 
FE No No Yes Yes 
 
* p < 0.10, ** p < 0.05, *** p < 0.01 
Note: This table presents various model specifications of ATET for formal care, excluding patients with change in formal 
care use>200 hours from baseline to 9-month follow-up. The first three columns include an interaction term where we 
look at the post-treatment period as one period, while in column (4) we look at each post-treatment period separately. 
Column (1) shows the results with no control variables or fixed effects. In column (2), time-invariant and time-variant 
control variables are included, and in column (3) and (4) time-variant control variables and fixed effects are included. 
Time-invariant control variables include baseline measurement of pain, depression, agitation, ADL and neuropsychiatric 
symptoms score, marital status, age and sex. The time-variant control is change of cognition score over time. Standard 




Appendix 7 Regressions without fixed effects 
ATET of COSMOS on QoL 










   




   




   











   




   



















   




   




   




   









Observations 411 411 
* p < 0.10, ** p < 0.05, *** p < 0.01 
Cluster bootstrapped standard errors in parentheses. Note: This table presents the ATET for use of psychotropic drugs. Column 
(1) include an interaction term where we look at the post-treatment period as one period, while in column (2) we look at each 
post-treatment period separately. Control variables include baseline measurement of pain, depression, agitation, ADL and 
neuropsychiatric symptoms score, change of cognition score over time, age, marital status and sex. Standard errors are 







ATET of COSMOS on categories of formal care 
 (1) (2) (3) (4) (5) (6) 


























       












       












       



























       












       



















































       












       












       












       

























Observations 411 411 411 411 411 411 
* p < 0.10, ** p < 0.05, *** p < 0.01 
Cluster bootstrapped standard errors in parentheses. 
Note: This table presents the ATET for three categories of formal care. Columns (1), (3), and (5) include an interaction term 
where we look at the post-treatment period as one period, while in column (4) we look at each post-treatment period separately. 
Control variables include baseline measurement of pain, depression, agitation, ADL and neuropsychiatric symptoms score, 











ATET of COSMOS on informal care  





































        



































































        































































































































































Observations 411 411 411 411 411 411 411 
* p < 0.10, ** p < 0.05, *** p < 0.01 
Cluster bootstrapped standard errors in parentheses. Note: This table presents the ATET for informal care and categories of 
informal care. Columns (1), (3), (5), and (6) include an interaction term where we look at the post-treatment period as one 
period, while in columns (2) and (4) we look at each post-treatment period separately. Control variables include baseline 
measurement of pain, depression, agitation, ADL and neuropsychiatric symptoms score, change of cognition score over time, age 






ATET of COSMOS on use of psychotropic medication 










   




   




   











   




   



















   




   




   




   









Observations 411 411 
* p < 0.10, ** p < 0.05, *** p < 0.01 
Cluster bootstrapped standard errors in parentheses.  
Note: This table presents the ATET for use of psychotropic drugs. Column (1) include an interaction term where we look at the 
post-treatment period as one period, while in column (2) we look at each post-treatment period separately. Control variables 
include baseline measurement of pain, depression, agitation, ADL and neuropsychiatric symptoms score, change of cognition 












Appendix 9 Change in hospital admissions 
  
 
 
